Solid-phase driven reactions of radioactive compounds.

JP2023541892A5Inactive Publication Date: 2024-11-28プレシリックス·ナームローゼ·ベンノートシヤープ
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023516121
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-09-11
Filing Date
2021-09-07
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for post-labeling reactions of radioactive compounds, particularly hydrolytic removal of protecting groups, face challenges with high activation barriers, requiring long reaction times and harsh conditions, and lack precise temperature control, especially when using disposable containers.

Method used

A method involving a controlled heating process for radioactive compounds, using a solid phase and temperatures between 30°C to 150°C, without contacting the solid phase with alkaline solutions, to perform post-labeling reactions efficiently, minimizing radiolysis and achieving high yields.

Benefits of technology

The method enables rapid post-labeling reactions with reduced radiolysis and high yields, allowing for precise temperature control and compatibility with various containers, including disposables, while maintaining the integrity of the radioactive compounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000068_0000
    Figure 00000068_0000
  • Figure 00000068_0001
    Figure 00000068_0001
  • Figure 00000068_0002
    Figure 00000068_0002
Patent Text Reader

Abstract

The present invention provides methods for carrying out chemical reactions of radioactive compounds, as well as devices, systems, and methods for improved heating for chemical reactions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of reactions of radioactively labeled compounds propelled by a solid phase, and to heating devices and systems for carrying out such reactions.

Background Art

[0002] The synthesis of radioactive reaction products typically involves a labeling reaction of a non-radioactive compound to form a radioactive compound called a precursor, followed by a post-labeling reaction of the precursor to form a radioactive reaction product. Many post-labeling reactions, including but not limited to, the hydrolytic removal of protecting groups, are characterized by high activation barriers. Nevertheless, such reactions are typically carried out at room temperature or slightly elevated temperatures, for example, 20°C to 30°C, because higher temperatures can lead to an increase in radiolysis and / or unwanted side reactions. Therefore, those post-labeling reactions with high activation barriers are carried out in the art under long reaction times and / or harsh reaction conditions. For example, Mosdzianowski et al. (2002) [1] showed that using a temperature of 60°C results in unwanted isomerization reaction products during hydrolysis with a strong base (12N NaOH) catalyst, even when a solid phase is used.

[0003] Therefore, there remains an unmet need in the art for a method of carrying out post-labeling reactions, specifically hydrolysis, of radioactively labeled compounds with short reaction times, without significant radiolysis, and in good yields.

[0004] Furthermore, while such post-labeling reactions require controlled heating, they are typically carried out in disposable reaction vessels. Therefore, there is a need for controlled heating suitable for use with various vessels, including disposable vessels.

[0005] U.S. Patent No. 8,476,063,B2 [2] discloses a device and method comprising a chamber heated by means of a heating element included as an attachment. However, the heating described in U.S. Patent No. 8,476,063,B2 lacks precision and temperature control and is excessively complex.

[0006] Heating means are provided in U.S. Patent Publication No. 20020183660A1[3], U.S. Patent No. 9408257B2[4], and Korean Patent No. 101320762B1[5], but none of them are suitable for use with chemical reaction vessels. Furthermore, these devices are overly complex and / or do not allow for adequate temperature control. [Overview of the project] [Means for solving the problem]

[0007] Method for carrying out post-labeling chemical reactions General characteristics In a first embodiment, the present invention provides a method for carrying out a chemical reaction of a radioactive compound contained in a mixture, wherein the method includes (a) contacting the mixture with a solid phase, and subsequently (b) heating the mixture to a temperature selected in the range of 30°C to a maximum of 150°C, wherein steps (a) and (b) do not involve contacting the solid phase with an alkaline solution, and wherein the chemical reaction does not result in the formation of new bonds on the radionuclides contained in the radioactive compound. Such a method is referred to in this application as the method according to the present invention or the method of the present invention. In the context of this application, the radioactive compound does not include fluorine-18. The (chemical) reaction according to the present invention or the (chemical) reaction of the present invention is a chemical reaction that can be carried out by applying the method according to the present invention.

[0008] Examples 1 and 2 utilize a solid phase (tC18) and high temperature (40-75°C) to produce a radioactive compound (Boc2-[ 131It has been demonstrated, for example, that it is possible to induce the [I]-SGMIB) reaction.

[0009] A chemical reaction of a compound is defined as the conversion of the compound to a reaction product, where such conversion includes the formation and / or rupture of one or more (chemical) bonds in the compound. Furthermore, the compound and the reaction product may have the same number and / or the same type of chemical bonds. For example, a chemical reaction of a compound may be racemization or isomerization of the compound. However, the interconversion of conformers is not considered a chemical reaction unless it involves only the rotation of covalent bonds and does not involve the rupture / formation of any bonds. In the context of this application, the terms “chemical reaction” and “reaction” are used interchangeably. The reaction product of a chemical reaction is defined herein as the various compounds formed during the chemical reaction.

[0010] Chemical bonds (also referred to in the context of this application) are various types of chemical bonds known to those skilled in the art, including, but not limited to, covalent bonds, ionic bonds, polar bonds, or hydrogen bonds. Preferably, the (chemical) bond refers to a covalent bond. According to this preferred definition, the results of the methods according to the present invention include the formation and / or breaking of covalent bonds.

[0011] A chemical reaction may include two or more chemical reactions as defined above. For example, the conjugation of an antibody fragment to a radiolabeled compound may include the step of hydrolyzing the protecting group of the radiolabeled compound to obtain a deprotected compound, and subsequently condensing the deprotected compound with the antibody fragment. In the context of the present invention, a chemical reaction may include several reaction steps. The reaction steps of a given reaction are defined as the various reactions included in the given reaction. Therefore, a method for carrying out a reaction includes, by definition, a method for carrying out each reaction step included in the reaction.

[0012] A method for carrying out a chemical reaction of a radioactive compound means to cause the chemical reaction to occur. This can be carried out by controlling one or more environmental factors, such as temperature, and by occupying together the compounds necessary for the reaction, such as the radioactive compound, and optionally other reactants, solvents, and / or catalysts. In this case, controlling one or more environmental factors or occupying together the compounds necessary for the reaction should not be interpreted as meaning that the chemical reaction proceeds as a one-pot reaction (in which case all reactants, solvents, and catalysts are in contact simultaneously). The reaction products of a method for carrying out a chemical reaction are defined herein as the reaction products of the chemical reaction.

[0013] A heating step included in the method according to the present invention includes heating the mixture to a temperature selected in the range of 30°C to a maximum of 150°C.

[0014] Preferably, the heating time is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 minutes. More preferably, the heating time is selected from the following ranges: 1 minute, up to 240 minutes, up to 210 minutes, up to 180 minutes, up to 150 minutes, up to 120 minutes, up to 110 minutes, up to 100 minutes, up to 90 minutes, up to 80 minutes, up to 70 minutes, up to 60 minutes, up to 50 minutes, up to 40 minutes, up to 30 minutes, up to 20 minutes, up to 19 minutes, up to 18 minutes, up to 17 minutes, up to 16 minutes, up to 15 minutes, up to 14 minutes, up to 13 minutes, up to 12 minutes, up to 11 minutes, up to 10 minutes, up to 9 minutes, up to 8 minutes, up to 7 minutes, up to 6 minutes, and up to 5 minutes.

[0015] Preferably, the heating of the mixture is at a temperature selected from the following ranges: 30°C up to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, the heating of the mixture is at a temperature selected from the following ranges: 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, or 65°C up to a maximum of 70°C. Preferably, the heating of the mixture is at a temperature selected from the following ranges: 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, or 145°C, up to a maximum of 150°C.

[0016] Preferably, the heating of the mixture is at a temperature selected from the following ranges: 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, or 145°C, each within a range of ±10°C. Preferably, the heating of the mixture is at a temperature selected from the following ranges: 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, or 140°C, each within a range of ±20°C. Preferably, the heating of the mixture is at a temperature selected from the following ranges: 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, or 135°C, each within a range of ±30°C. Preferably, the heating of the mixture is at a temperature selected from the following ranges: 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, or 130°C, each within a range of ±40°C. Preferably, the heating of the mixture is at a temperature selected from the following ranges: 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, or 125°C, each within a range of ±50°C.

[0017] Preferably, the heating of the mixture is at a temperature selected in the range of 30°C to a maximum of 70°C, and the heating time is selected in the range of 1 minute to a maximum of 15 minutes, or the heating of the mixture is at a temperature selected in the range of 30°C to a maximum of 55°C, and the heating time is selected in the range of 1 minute to a maximum of 15 minutes, or the heating of the mixture is at a temperature selected in the range of 30°C to a maximum of 70°C, and the heating time is selected in the range of 1 minute to a maximum of 10 minutes. Or, the heating of the mixture is at a temperature selected from 30°C to a maximum of 55°C, and the heating time is selected from 1 minute to a maximum of 10 minutes, or the heating of the mixture is at a temperature selected from 30°C to a maximum of 70°C, and the heating time is selected from 1 minute to a maximum of 5 minutes, or the heating of the mixture is at a temperature selected from 30°C to a maximum of 55°C, and the heating time is selected from 1 minute to a maximum of 5 minutes.

[0018] In the context of the method according to the present invention, heating the mixture at a predetermined temperature for a predetermined time means applying heat to the solid phase and the mixture used in the method for the predetermined time so that the mixture reaches the predetermined temperature after the equilibrium time, and maintaining the temperature of the mixture at the predetermined temperature for the remainder of the time. It should be understood that the equilibrium time is shorter than the predetermined time. The mixture has reached the predetermined temperature, or the temperature of the mixture is at the predetermined temperature, if the (spatial) average temperature of the mixture deviates from the predetermined temperature by no more than 1°C, preferably no more than 0.5°C, and more preferably no more than 0.2°C. The (spatial) average temperature can be measured using a simple thermometer immersed in a fluid that is thermally equilibrium with the mixture.

[0019] Preferably, the time to reach equilibrium is from 180 seconds, or 170 seconds, or 160 seconds, or 150 seconds, or 140 seconds, or 130 seconds, or 120 seconds, or 110 seconds, or 100 seconds, or 90 seconds, or 80 seconds, or 70 seconds, or 60 seconds, or 50 seconds, or 40 seconds, or 30 seconds, or 20 seconds, or 10 seconds, down to a minimum of 1 second; more preferably, the time to reach equilibrium is from 60 seconds to a minimum of 1 second.

[0020] A mixture having a homogeneous temperature distribution is a mixture that, when measured with an infrared temperature sensor, has a temperature at any point in space that is no more than 1°C, preferably 0.5°C, and more preferably 0.2°C, that deviates from the spatial average temperature of the mixture. In all embodiments of this specification, a mixture having a predetermined temperature is preferably a mixture having a homogeneous temperature distribution.

[0021] The yield of the reaction product of a chemical reaction involving a radioactive compound is defined as the ratio of the number of molecules of the reaction product formed during the reaction to the total number of molecules of the radioactive compound at the start of the reaction. In the context of this definition, it should be understood that the total number includes molecules that could be considered as the radioactive compound and were capable of reacting in the chemical reaction, but nevertheless did not result in the reaction product during the chemical reaction. For example, the yield of a hydrolysis reaction may be less than 100% due to unreacted radioactive compounds and / or side reactions that result in other reaction products. The yield is preferably measured by quantitative HPLC, as is well known to those skilled in the art.

[0022] When referring to the yield of the reaction product, or product yield, the reaction product is the reaction product of the chemical reaction in this invention, and is as previously defined. Furthermore, unless otherwise specified, it is implicitly assumed in this application that the concentration of the radioactive compound at the start of the reaction is stoichiometrically limited. Moreover, the yield is defined by the conditions under which the chemical reaction is carried out, including parameters such as heating temperature and time.

[0023] The yield of a chemical reaction is defined as the yield of the desired reaction product of the chemical reaction, where the desired reaction product is specified or is evident from the context. For example, in direct relation to the definition below, the yield of hydrolytic deprotection preferably refers to the yield of the completely deprotected reaction product unless otherwise specified.

[0024] Accordingly, the yield of the reaction product at the end of step (b) or step (c) in the method according to the present invention is defined as the ratio of the number of molecules of the reaction product obtained at the end of step (b) or (c) to the total number of molecules of the radioactive compound at the start of the reaction.

[0025] Preferably, the yield of the reaction in the present invention, or the reaction steps contained therein (the yield of the desired reaction product) is at least 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, and 67.5%. The percentages are %, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 90.5%, 91%, 91.5%, 92%, 92.5%, 93%, 93.5%, 94%, 94.5%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, or 99.5%. Preferably, when referring to the yield of a reaction or reaction step, or the yield of their reaction products, without specifying the conditions, the yield at which the reaction or reaction step is carried out refers to the yield 5 minutes or 10 minutes after heating. More preferably, when referring to a reaction or reaction step, or the yield of such reaction products, without specifying the conditions, the yield at which the reaction or reaction step is carried out refers to the yield after 5 minutes of heating at 30°C, 35°C, 40°C, 45°C, 50°C, or 55°C.

[0026] A mixture of reaction products is defined as a composition isolated after the reaction of a radioactive compound is complete, for the purpose of recovering the desired reaction product of the reaction, wherein the composition contains the desired reaction product, and the isolation may involve the use of one or more purification methods known to those skilled in the art, such as affinity purification, filtration, centrifugation, evaporation, liquid-liquid extraction, crystallization, recrystallization, adsorption, chromatography, distillation, fractionation, electrolysis, or sublimation.

[0027] The purity of the reaction product of a chemical reaction of a radioactive compound is defined as the concentration of the reaction product in a mixture of reaction products. Preferably, the purity is the ratio of the mass of the reaction product contained in the mixture of reaction products to the total mass of the mixture of reaction products. The purity is measured by measuring the concentration of the desired reaction product using a method similar to that of yield, i.e., by quantitative HPLC or TLC, as is well known to those skilled in the art. When referring to the purity of a product, i.e., product purity, the reaction product is the reaction product of the chemical reaction in this invention and is as previously defined.

[0028] Preferably, the purity of the reaction in the present invention, or the desired reaction product of the reaction steps contained therein, is at least 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, The percentages are 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 90.5%, 91%, 91.5%, 92%, 92.5%, 93%, 93.5%, 94%, 94.5%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, or 99.5%.

[0029] Chemical reactions, particularly those involving radioactive compounds, often exhibit high activation barriers. A chemical reaction with a high activation barrier is defined as one that, in order to obtain a yield of at least 50% of the desired reaction product, must be carried out in the absence of a catalyst or facilitator, preferably in the absence of a solid phase capable of functioning as a facilitator in the reaction, under the following conditions: 30 minutes at 50°C, or 30 minutes at 60°C, or 30 minutes at 70°C, or 30 minutes at 80°C, or 30 minutes at 90°C, or 30 minutes at 100°C, or 30 minutes at 110°C, or 12 minutes. 30 minutes at 0°C, or 30 minutes at 130°C, or 30 minutes at 140°C, or 30 minutes at 150°C, or 60 minutes at 50°C, or 60 minutes at 60°C, or 60 minutes at 70°C, or 60 minutes at 80°C, or 60 minutes at 90°C, or 60 minutes at 100°C, or 60 minutes at 110°C, or 60 minutes at 120°C, or 60 minutes at 130°C, or 60 minutes at 140°C, or 60 minutes at 150°C, or 90 minutes at 50°C, or 90 minutes at 60°C, or 90 minutes at 70°C, or 90 minutes at 80°C, or 90 minutes at 90°C. , or 100°C for 90 minutes, or 110°C for 90 minutes, or 120°C for 90 minutes, or 130°C for 90 minutes, or 140°C for 90 minutes, or 150°C for 90 minutes, or 50°C for 120 minutes, or 60°C for 120 minutes, or 70°C for 120 minutes, or 80°C for 120 minutes, or 90°C for 120 minutes, or 100°C for 120 minutes, or 110°C for 120 minutes, or 120°C for 120 minutes, or 130°C for 120 minutes, or 140°C for 120 minutes, or 150°C for 120 minutes, or 50°C for 150 minutes, if or 60°C for 150 minutes, or 70°C for 150 minutes, or 80°C for 150 minutes, or 90°C for 150 minutes, or 100°C for 150 minutes, or 110°C for 150 minutes, or 120°C for 150 minutes, or 130°C for 150 minutes, or 140°C for 150 minutes, or 150°C for 150 minutes, or 50°C for 180 minutes, or 60°C for 180 minutes, or 70°C for 180 minutes, or 80°C for 180 minutes, or 90°C for 180 minutes, or 100°C for 180 minutes, or 110°C for 180 minutes, or 120°C for 180 minutes.Alternatively, 180 minutes at 130°C, or 180 minutes at 140°C, or 180 minutes at 150°C, or 210 minutes at 50°C, or 210 minutes at 60°C, or 210 minutes at 70°C, or 210 minutes at 80°C, or 210 minutes at 90°C, or 210 minutes at 100°C, or 210 minutes at 110°C, or 210 minutes at 120°C, or 210 minutes at 130°C, or 140 210 minutes at °C, or 210 minutes at 150 °C, or 240 minutes at 50 °C, or 240 minutes at 60 °C, or 240 minutes at 70 °C, or 240 minutes at 80 °C, or 240 minutes at 90 °C, or 240 minutes at 100 °C, or 240 minutes at 110 °C, or 240 minutes at 120 °C, or 240 minutes at 130 °C, or 240 minutes at 140 °C, or 240 minutes at 150 °C. In one preferred embodiment, a method according to the present invention is provided in which the chemical reaction has a high activation barrier.

[0030] In the context of this application, a catalyst is a compound that increases the reaction rate of the reaction in the present invention, wherein the catalyst forms a coordination bond or equivalent bond, preferably a covalent bond, with one or more of the reactants in the reaction in the present invention. In the context of this application, a facilitator is a compound that increases the reaction rate of the reaction in the present invention, wherein the facilitator does not form a covalent bond with the reactants in the reaction in the present invention. Preferably, a catalyst or facilitator is defined as a compound that lowers the temperature required to carry out the reaction in the present invention compared to the same reaction for the same amount of time in the absence of the catalyst or facilitator, for the purpose of obtaining the same yield of reaction product, wherein the same reaction means using the same reactants in substantially the same amounts. Preferably, the temperature can be lowered by at least 5°C, 10°C, 15°C, 20°C, 25°C, 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, or 100°C. In this definition, the chemical reaction in the present invention is preferably a chemical reaction having a high activation barrier. As experienced practitioners will understand, catalysts or facilitators as defined above can be used to lower the temperature and / or shorten the reaction time required to carry out a reaction using the same reactants to obtain the same yield of reaction products.

[0031] Furthermore, as is understood by experts in the field, the catalyst or facilitator may act by a different mechanism. Preferably, the solid phase used in the method according to the present invention is a facilitator for the chemical reaction of the radioactive compound, wherein the facilitator increases the reaction rate by increasing the local concentration of the radioactive compound and / or other reactants, reaction products, or other compounds contained in the reaction.

[0032] In the method according to the present invention, the radioactive compound is contained in a mixture. The mixture is a solution or colloid containing the radioactive compound. Preferably, the mixture is an aqueous solution or an aqueous colloid. More preferably, the mixture is an aqueous solution having a pH lower than 14, 13.5, 13, 12.5, 12, 11.5, 11, 10.5, 10, 9.5, 9, 8.5, 8, 7.5, 7, 6.5, 6, 5.5, 5, 4.5, or 4. Preferably, the mixture contains a facilitator for carrying out the chemical reaction, and more preferably, the facilitator is a solid phase as defined herein.

[0033] The solid phase used in the method according to the present invention may be any compound in a solid state that is suitable for contact with the mixture containing the radioactive compound during the reaction as defined above. Suitable in this context means that the solid phase should enable the reaction to occur under desired or specific reaction conditions. For example, if the reaction of the radioactive compound is to be carried out in a given solvent at a given temperature, the solid phase must not degrade in the solvent at the given temperature, and preferably, the solid phase should act as a facilitator to allow the reaction to occur at the given temperature.

[0034] In one preferred embodiment, a method according to the present invention is provided, wherein the solid phase is a facilitator for the chemical reaction of the radioactive compound, and preferably the chemical reaction has a high activation barrier. Generally and specifically in the context of this preferred embodiment, it will be understood that the reaction may have multiple catalysts and / or facilitators. Therefore, the solid phase, which is a facilitator for the chemical reaction, does not exclude or imply the presence of other catalysts and / or facilitators in the reaction or in the mixture.

[0035] An alkaline solution is defined as a solution in a strong base solvent. Preferably, the strong base is a strong organic base, such as triethylamine, or a strong inorganic base, more preferably an alkali metal, such as a hydroxide of lithium (Li), sodium (Na), potassium (K), rubidium (Rb), cesium (Cs), or francium (Fr), or an alkaline earth metal, such as a hydroxide of beryllium (Be), magnesium (Mg), calcium (Ca), strontium (Sr), barium (Ba), or radium (Ra). Preferably, the solvent is water or an organic base, such as tetrabutylammonium carbonate (TBAC).

[0036] More preferably, the alkaline solution is an aqueous solution having a pH of at least 8, 8.2, 8.4, 8.6, 8.8, 9, 9.2, 9.4, 9.6, 9.8, 10, 10.2, 10.4, 10.6, 10.8, 11, 11.2, 11.4, 11.6, 11.8, 12, 12.2, 12.4, 12.6, 12.8, 13, 13.2, 13.4, 13.6, 13.8, or 14. According to this preferred definition, steps (a) and (b) of the method according to the present invention do not involve contacting the solid phase with an aqueous solution having a pH higher than 14, 13.8, 13.6, 13.4, 13.2, 13, 12.8, 12.6, 12.4, 12.2, 12, 11.8, 11.6, 11.4, 11.2, 11, 10.8, 10.6, 10.4, 10.2, 10, 9.8, 9.6, 9.4, 9.2, 9, 8.8, 8.6, 8.4, 8.2, or 8.

[0037] In the context of this application, the expression “wherein steps (a) and (b) do not involve contacting the solid phase with an alkaline solution” as expressed in relation to the method according to the present invention can be replaced with the expression “wherein any solution that comes into contact with the solid phase in steps (a) and (b) is a neutral or acidic solution.” Therefore, the method according to the present invention can thus be expressed as follows: a method for carrying out a chemical reaction of a radioactive compound contained in a mixture, wherein the method comprises the steps of (a) contacting the mixture with a solid phase, and (b) heating the mixture to a temperature selected in the range of 30°C to a maximum of 150°C, wherein all solutions that come into contact with the solid phase in steps (a) and (b) are neutral or acidic solutions, wherein the chemical reaction does not result in the formation of new bonds on the radionuclides contained in the radioactive compound, wherein the radioactive compound does not contain fluorine-18.

[0038] In one preferred embodiment, a method according to the present invention is provided as follows: During step (b), the solid phase is in contact with the mixture containing the radioactive compound. Therefore, in this embodiment, the mixture containing the radioactive compound is not an alkaline solution. In other words, in this embodiment, the mixture containing the radioactive compound is a neutral or acidic solution.

[0039] In one preferred embodiment, a method according to the present invention is provided as follows: any heating (step) involving contacting the solid phase with a solution does not involve contacting the solid phase with an alkaline solution. In other words, in this embodiment, any solution that comes into contact with the solid phase during the heating (step) is a neutral or acidic solution.

[0040] In one preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction does not include a reaction step, and wherein an alkaline solution is not used and / or the solid phase is not brought into contact with an alkaline solution. Preferably, the alkaline solution is an aqueous solution having a pH of at least 8, 8.2, 8.4, 8.6, 8.8, 9, 9.2, 9.4, 9.6, 9.8, 10, 10.2, 10.4, 10.6, 10.8, 11, 11.2, 11.4, 11.6, 11.8, 12, 12.2, 12.4, 12.6, 12.8, 13, 13.2, 13.4, 13.6, 13.8, or 14.

[0041] Whenever a chemical reaction, reaction step, or part thereof is said to be free from or use of a particular compound, composition, or mixture thereof, it means that the compound, composition, or mixture thereof is not present in the reaction medium during the reaction, reaction step, or part thereof, or is present only at a concentration of less than 0.1% by weight, 0.01% by weight, 0.001% by weight, or 0.0001% by weight, or is undetectable by quantitative HPLC, and does not come into contact with or is not in direct contact with the reactants and / or reaction products, reaction step, or part thereof of the reaction. For example, a reaction of a radioactive compound contained in a mixture that does not contain an alkaline solution cannot occur in the presence of a dissolved strong base. Nevertheless, an alkaline solution can be used, as long as it does not come into direct contact with the mixture.

[0042] A radioactive compound is a compound that contains a radionuclide. A radionuclide is a thermodynamically unstable nucleus that, as a natural phenomenon, transforms into a stable nucleus through internal conversion, which generates radioactive particles. This conversion of a radionuclide into a stable nucleus is called radioactive decay, and it emits gamma rays (γ) and / or subatomic particles, such as alpha (α) or beta (β) particles. A beta (β) particle is an electron (β) - ) or positron (β+ ) may be such. Their emissions constitute ionizing radiation. In this application, the terms radionuclide, radioactive nuclide, radioisotope, and radioactive isotope are used interchangeably. Furthermore, radionuclide also refers to an atom containing the radionuclide. For example, a radionuclide on or bonded to a radionuclide, or a salt of a radionuclide, is also defined in this sense. It is preferable that the radioactive compound contains one or fewer radionuclides.

[0043] The loss of a radionuclide contained in a radioactive compound, also known as radiolysis or radiolytic degradation of the radioactive compound, is defined as the breaking of bonds between the radionuclide and other atoms contained in the radioactive compound, or the breaking of bonds between other atoms of the radioactive compound caused by the transfer of linear energy by the radionuclide, after which the radionuclide is no longer part of the compound or is bound only to fragments of the radioactive compound. Preferably, the loss of a radionuclide such that the radioactive compound contains only one radionuclide and not two or more results in a non-radioactive compound and a fraction of the radioactive compound containing the released radionuclide. From the standpoint of this definition, it is understood by those skilled in the art that the fraction of the radioactive compound is undesirable, i.e., a by-product. For example, in the case of a deprotection reaction of a (protected) radioactive compound, the deprotected reaction product is not considered a fraction of the radioactive compound.

[0044] The degree of radiolysis in a chemical reaction of a radioactive compound is defined as the ratio of the number of molecules of the radioactive compound that lost radionuclides during the chemical reaction to the total number of molecules of the radioactive compound at the start of the chemical reaction.

[0045] Accordingly, the degree of radiolysis can also be defined at various reaction steps included in the reaction of the present invention, or at various steps or time intervals included in the reaction of the present invention, or in the method according to the present invention. For example, the degree of radiolysis during heating (b) included in the method according to the present invention is defined as the ratio between the number of molecules of the radioactive compound that have been lost as radionuclides during the heating and the total number of molecules of the radioactive compound at the start of the heating.

[0046] Preferably, in the reaction according to the present invention, the radioactive compound is converted into a radioactive reaction product, that is, the reaction product contains a radionuclide. More preferably, the radioactive compound and the radioactive reaction product contain the same radionuclide. In other words, the loss of the radionuclide of the radioactive compound can be considered an undesirable side reaction in the reaction according to the present invention.

[0047] In one preferred embodiment, a method according to the present invention is provided, wherein the degree of radiolysis during the chemical reaction is lower than 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1%.

[0048] In one preferred embodiment, the following method according to the present invention is provided, wherein the chemical reaction does not involve the loss of radionuclides contained in the radioactive compound.

[0049] In one preferred embodiment, a method according to the present invention is provided, wherein the degree of radiolysis during heating (b) is lower than 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1%. Preferably, the degree of radiolysis refers to the yield at 5 or 10 minutes after heating, more preferably the degree of radiolysis at 5 minutes after heating, for heating at 30°C, 35°C, 40°C, 45°C, 50°C, or 55°C.

[0050] In one preferred embodiment, the following method according to the present invention is provided, wherein the heating (b) does not involve the radioactive decay of the compound and / or the loss of radionuclides contained in the radioactive compound.

[0051] Furthermore, radioactive compounds are susceptible to radioactive decay, which is defined as the radioactive decay of at least one radionuclide contained in the radioactive compound, preferably all radionuclides contained in the radioactive compound. If the compound contains radionuclides that can undergo radioactive decay by emitting alpha particles, beta particles, or gamma rays, or Auger electrons, the radioactive compound is called an alpha-emitter, beta-emitter, or gamma-emitter, or an Auger-emitter. In this case, it should be understood that the radioactive compound may emit two or more types of particles or radiation.

[0052] Since radioactive compounds are prone to both radiolysis and radioactive decay, the contact time of all reactants should be kept to a minimum.

[0053] A post-labeling (chemical) reaction of a radioactive compound is defined as a chemical reaction of the radioactive compound that does not result in the formation of new bonds on the radionuclides contained in the radioactive compound. For example, the transfer of a radionuclide between two compounds via nucleophilic substitution cannot be considered a post-labeling reaction, whereas nucleophilic substitution of another residue contained in the radioactive compound can be considered a post-labeling reaction. Not bound by this theory, the preparation of a radioactive compound of interest typically involves a labeling reaction, in which a radionuclide is bound to a non-radioactive compound to form a radioactive intermediate, followed by one or more post-labeling reactions of the radioactive intermediate, in which the post-labeling reactions do not change the characteristics of the binding of the radionuclide to the intermediate, as understood by experts in the field.

[0054] The reaction in the present invention is a post-labeling reaction. In the context of this application, the expression “does not result in the formation of new bonds on the radionuclides contained in the radioactive compound” as defined in relation to the method according to the present invention can be replaced with the expression “the chemical reaction is a post-labeling reaction.” In other words, the method according to the present invention can be expressed as follows: a method for carrying out a chemical reaction of a radioactive compound contained in a mixture, wherein the method comprises (a) contacting the mixture with a solid phase, followed by (b) heating the mixture to a temperature selected in the range of 30°C to a maximum of 150°C, wherein steps (a) and (b) do not involve contacting the solid phase with an alkaline solution, wherein the chemical reaction is a post-labeling reaction, wherein the radioactive compound does not contain fluorine-18.

[0055] In view of the above, the method according to the present invention can be expressed as follows: a method for carrying out a chemical reaction of a radioactive compound contained in a mixture, wherein the method comprises (a) a step of contacting the mixture with a solid phase, and subsequently (b) a step of heating the mixture to a temperature selected in the range of 30°C to a maximum of 150°C, wherein all solutions in contact with the solid phase in steps (a) and (b) are neutral or acidic solutions, wherein the chemical reaction is a post-labeling reaction, and wherein the radioactive compound does not contain fluorine-18.

[0056] As is well known to those skilled in this field, radioactive compounds may contain stereogenic centers, i.e., asymmetrically substituted atoms, where the asymmetric substitution imparts chiral properties such as plane polarization rotation or stereospecific or stereoselective catalysis by enzymes. It is preferable that the stereogenic centers are asymmetrically substituted tetravalent carbon atoms. Each stereogenic center contained in the radioactive compound may exist in one of two (stereo)configurations, where the configurations do not differ in the type and amount of bonds between atoms contained in the radioactive compound. Isomerization of a stereogenic center contained in a radioactive compound is defined as the conversion of one configuration of the stereogenic center to another configuration. Enantiomorphism of a radioactive compound is defined as the isomerization of all stereogenic centers in the radioactive compound. Diastereoisomerization of a radioactive compound is defined as the isomerization of at least one, but not all, stereogenic centers in the radioactive compound.

[0057] In one preferred embodiment, the following method according to the present invention is provided, wherein the chemical reaction does not involve isomerization, diastereoisomerization, or enantiomorphization of the radioactive compound.

[0058] In one more preferred embodiment, a method according to the present invention is provided, wherein (a) contact with a solid phase and / or (b) heating does not involve isomerization, diastereoisomerization, or enantiomorphization of the radioactive compound.

[0059] In yet another, more preferred embodiment, the following method according to the present invention is provided, wherein the various isomerization reactions, i.e., those included in (a) contact with the solid phase and / or (b) heating, have yields lower than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1%.

[0060] Type of reaction In one preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises solvolysis of the radioactive compound, preferably, wherein the solvolysis occurs during heating. The solvolysis of the radioactive compound is a reaction between the radioactive compound and a solvent, wherein the reaction comprises the breaking of bonds in the radioactive compound, preferably, wherein the reaction comprises the formation of bonds between atoms contained in the solvent and atoms contained in the radioactive compound. Examples of solvolysis include transesterification, displacement, or substitution of leaving groups by solvent, dehydration, and hydrolysis.

[0061] Solvolysis preferably refers to a reaction between a nucleophilic solvent and the radioactive compound, where a bond is formed between atoms in the radioactive compound and atoms in the nucleophilic solvent, and the reaction can be described as a nucleophilic substitution or elimination reaction of the radioactive compound, and preferably, the nucleophilic solvent is selected from the group consisting of water and alcohols, and most preferably, the nucleophilic solvent is water. It is preferable that the solvolysis does not involve the use of an alkaline solution.

[0062] In one more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the solvolysis of the radioactive compound, wherein the solvolysis occurs during heating, wherein the solvolysis has a high activation barrier, and preferably, wherein the solid phase is a facilitator for the solvolysis.

[0063] In the above preferred embodiments, the degree of radiolysis during solvolysis is preferably lower than 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1%. Preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected in the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C, and the heating time is selected in the range of 1 minute to a maximum of 10 minutes.

[0064] As is well known to those skilled in this field, solvolysis yields solvolysis reaction products. In the preferred embodiments above, the yield of the solvolysis reaction products is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected to be within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is at a temperature selected to be within the range of 30°C to a maximum of 55°C, and the heating time is selected to be within the range of 1 minute to a maximum of 10 minutes.

[0065] In one most preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises solvolysis of the radioactive compound, wherein the solvolysis occurs during heating, wherein the degree of radiolysis during the solvolysis is less than 5%, and wherein the yield of the reaction product of the solvolysis is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, The yield is 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%, preferably where the degree of radiolysis during the solvolysis is less than 3%, and where the yield of the reaction product of the solvolysis is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 10 minutes.

[0066] In one more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, preferably, wherein the hydrolysis occurs during heating. Preferably, the hydrolysis occurs in an aqueous solution at a pH lower than 7, 6.8, 6.6, 6.4, 6.2, 6, 5.8, 5.6, 5.4, 5.2, or 5. More preferably, the hydrolysis occurs in an aqueous solution with a pH ranging from 14, 13.8, 13.6, 13.4, 13.2, 13, 12.8, 12.6, 12.4, 12.2, 12, 11.8, 11.6, 11.4, 11.2, 11, 10.8, 10.6, 10.4, 10.2, 10, 9.8, 9.6, 9.4, 9.2, 9, 8.8, 8.6, 8.4, 8.2, 8, 7.8, 7.6, 7.4, 7.2, 7, 6.8, 6.6, 6.4, 6.2, 6, 5.8, 5.6, 5.4, 5.2, or 5 to a minimum of 1. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected to be within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is at a temperature selected to be within the range of 30°C to a maximum of 55°C, and the heating time is selected to be within the range of 1 minute to a maximum of 10 minutes.

[0067] In one more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, preferably wherein the hydrolysis occurs during heating, wherein the hydrolysis is acid hydrolysis, preferably wherein the acid hydrolysis comprises the use of an acid selected from the group consisting of phosphoric acid, hydrochloric acid, sulfuric acid, trifluoroacetic acid, and aqueous mixtures thereof, more preferably wherein the acid is selected from the group consisting of phosphoric acid, hydrochloric acid, sulfuric acid, and aqueous mixtures thereof, preferably wherein the acid is 50% by weight, 60% by weight, 70% by weight, 80% by weight, or 90% by weight of phosphoric acid, more preferably wherein the acid is 80% by weight of phosphoric acid. Preferably, the hydrolysis occurs in an aqueous solution at a pH lower than 7, 6.8, 6.6, 6.4, 6.2, 6, 5.8, 5.6, 5.4, 5.2, or 5. More preferably, the hydrolysis occurs in an aqueous solution with a pH ranging from 14, 13.8, 13.6, 13.4, 13.2, 13, 12.8, 12.6, 12.4, 12.2, 12, 11.8, 11.6, 11.4, 11.2, 11, 10.8, 10.6, 10.4, 10.2, 10, 9.8, 9.6, 9.4, 9.2, 9, 8.8, 8.6, 8.4, 8.2, 8, 7.8, 7.6, 7.4, 7.2, 7, 6.8, 6.6, 6.4, 6.2, 6, 5.8, 5.6, 5.4, 5.2, or 5 to a minimum of 1. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected to be within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is at a temperature selected to be within the range of 30°C to a maximum of 55°C, and the heating time is selected to be within the range of 1 minute to a maximum of 10 minutes.

[0068] In one more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the hydrolysis has a high activation barrier, and preferably, wherein the solid phase is a facilitator for the hydrolysis. The rate of the hydrolysis is further accelerated by using an acid selected from the group consisting of phosphoric acid, hydrochloric acid, sulfuric acid, trifluoroacetic acid, and aqueous mixtures thereof, more preferably, wherein the acid is 50% by weight, 60% by weight, 70% by weight, 80% by weight, or 90% by weight of phosphoric acid, and more preferably, wherein the acid is 80% by weight of phosphoric acid. Preferably, the hydrolysis occurs in an aqueous solution with a pH lower than 14, 13.8, 13.6, 13.4, 13.2, 13, 12.8, 12.6, 12.4, 12.2, 12, 11.8, 11.6, 11.4, 11.2, 11, 10.8, 10.6, 10.4, 10.2, 10, 9.8, 9.6, 9.4, 9.2, 9, 8.8, 8.6, 8.4, 8.2, 8, 7.8, 7.6, 7.4, 7.2, 7, 6.8, 6.6, 6.4, 6.2, 6, 5.8, 5.6, 5.4, 5.2, or 5. More preferably, the hydrolysis occurs in an aqueous solution with a pH ranging from 14, 13.8, 13.6, 13.4, 13.2, 13, 12.8, 12.6, 12.4, 12.2, 12, 11.8, 11.6, 11.4, 11.2, 11, 10.8, 10.6, 10.4, 10.2, 10, 9.8, 9.6, 9.4, 9.2, 9, 8.8, 8.6, 8.4, 8.2, 8, 7.8, 7.6, 7.4, 7.2, 7, 6.8, 6.6, 6.4, 6.2, 6, 5.8, 5.6, 5.4, 5.2, or 5 to a minimum of 1. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected to be within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is at a temperature selected to be within the range of 30°C to a maximum of 55°C, and the heating time is selected to be within the range of 1 minute to a maximum of 10 minutes.

[0069] In the above preferred embodiments, the degree of radiolysis during hydrolysis is preferably lower than 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1%. Preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected in the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C, and the heating time is selected in the range of 1 minute to a maximum of 10 minutes.

[0070] In the above preferred embodiment, the degree of radiolysis during the hydrolysis is preferably less than 5%, wherein the hydrolysis occurs during heating, wherein the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes, and the heating of the mixture is at a temperature selected from the following ranges: 30°C to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes, and the heating of the mixture is to a temperature selected from the range of 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, or 75°C, up to a maximum of 70°C.

[0071] As is well known to those skilled in this field, hydrolysis can yield hydrolytic reaction products. Such reaction products may be, for example, hydrolytically deprotected radioactive compounds, or carboxylic acids, or salts or ions thereof, resulting from the hydrolysis of an amide or ester group. In the above preferred embodiments, the yield of the hydrolytic reaction products is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 10 minutes.

[0072] In one more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the degree of radiolysis in the hydrolysis is less than 5%, and wherein the yield of the reaction product of the hydrolysis is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, The yield is 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%, preferably where the degree of radiolysis during the hydrolysis is less than 3%, and where the yield of the reaction product of the hydrolysis is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 10 minutes.

[0073] In one most preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the degree of radiolysis during the hydrolysis is less than 5%, and wherein the yield of the hydrolysis reaction product is at least 30%, preferably, wherein the degree of radiolysis during the hydrolysis is less than 3%, and wherein the yield of the hydrolysis reaction product is At least 35%, where the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes, and the heating of the mixture is to a temperature selected from the following ranges: 30°C to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 10 minutes, or the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 5 minutes. Most preferably, the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 10 minutes.

[0074] In another preferred embodiment, the following method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the degree of radiolysis during the hydrolysis is less than 5%, and wherein the yield of the hydrolysis reaction product is at least 30%, preferably, wherein the degree of radiolysis during the hydrolysis is less than 3%, and wherein the yield of the hydrolysis reaction product is at least 35%. % is such that the hydrolysis occurs in an aqueous solution with a pH lower than 14, 13.8, 13.6, 13.4, 13.2, 13, 12.8, 12.6, 12.4, 12.2, 12, 11.8, 11.6, 11.4, 11.2, 11, 10.8, 10.6, 10.4, 10.2, 10, 9.8, 9.6, 9.4, 9.2, 9, 8.8, 8.6, 8.4, 8.2, 8, 7.8, 7.6, 7.4, 7.2, 7, 6.8, 6.6, 6.4, 6.2, 6, 5.8, 5.6, 5.4, 5.2, or 5. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected to be within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is at a temperature selected to be within the range of 30°C to a maximum of 55°C, and the heating time is selected to be within the range of 1 minute to a maximum of 10 minutes.

[0075] In yet another, more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the degree of radiolysis during the hydrolysis is less than 5%, and wherein the yield of the hydrolysis reaction product is at least 30%, preferably, wherein the degree of radiolysis during the hydrolysis is less than 3%, and wherein the yield of the hydrolysis reaction product is at least 35%, The hydrolysis occurs in the aqueous solution at a pH lower than 7, wherein the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes, and the heating of the mixture is at a temperature selected from the following ranges: 30°C to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, the heating of the mixture is at a temperature selected from the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected from the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 10 minutes, or the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 5 minutes. Most preferably, the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 10 minutes.

[0076] In one most preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during the heating, wherein the yield of the hydrolysis reaction product is at least 30%, preferably, wherein the yield of the hydrolysis reaction product is at least 35%, wherein the hydrolysis occurs in an aqueous solution at a pH lower than 7, wherein the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes, and the heating of the mixture is at a temperature selected from the following ranges: 30°C to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 10 minutes, or the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 5 minutes. Most preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 10 minutes.

[0077] The radioactive compound used in the method according to the present invention may contain one or more protecting groups. As is well known to those skilled in the art, a protecting group is a functional group covalently bonded to the radioactive compound and serves the purpose of chemical selectivity of the chemical reaction, i.e., obtaining the desired final product in a predetermined yield, but here, the functional group is not covalently bonded to the desired final reaction product.

[0078] Preferably, the protecting group is selected from the group consisting of: tert-butylcarbamate (t-Boc), tert-butyl ester (OtBu), benzyl ester (BzO), benzylidene, tetrahydropyranyl ether (THP), acetal, trityl (Trt), and methoxymethyl ether (MOM). The protecting group is most preferably tert-butylcarbamate (t-Boc).

[0079] The removal of a protecting group (from a radioactive compound) is defined as a chemical reaction of the radioactive compound in which the covalent bond between the protecting group and other atoms in the radioactive compound is broken. The reaction product of such removal is called a deprotected radioactive compound. The removal of a protecting group is also called deprotection. Solvolysis and hydrolysis as defined above preferably include the removal of a protecting group from a radioactive compound.

[0080] In one preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises solvolysis of the radioactive compound, wherein the solvolysis occurs during heating, wherein the solvolysis comprises the removal of a protecting group from the radioactive compound, preferably, wherein the protecting group is selected from the group consisting of tert-butylcarbamate (t-Boc), tert-butyl ester (OtBu), benzyl ester (BzO), benzylidene, tetrahydropyranyl ether (THP), acetal, trityl (Trt), and methoxymethyl ether (MOM), most preferably, wherein the protecting group is tert-butylcarbamate (t-Boc).

[0081] In one preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the hydrolysis comprises the removal of a protecting group from the radioactive compound, preferably, wherein the protecting group is selected from the group consisting of tert-butylcarbamate (t-Boc), tert-butyl ester (OtBu), benzyl ester (BzO), benzylidene, tetrahydropyranyl ether (THP), acetal, trityl (Trt), and methoxymethyl ether (MOM), most preferably, wherein the protecting group is tert-butylcarbamate (t-Boc).

[0082] As explained above, it is preferable that the radioactive compound contains two or more protecting groups. In one embodiment, the following method according to the present invention is provided, wherein the radioactive compound contains exactly one, two, three, or four protecting groups, and less than or equal to the aforementioned number. In another embodiment, the following method according to the present invention is provided, wherein the radioactive compound contains two or more protecting groups. The radioactive compound used in the latter preferred method is called a radioactive compound having multiple protecting groups.

[0083] The complete removal of protecting groups from a radioactive compound is also called complete deprotection or total deprotection, and is defined as the removal of all protecting groups contained in a radioactive compound having multiple protecting groups. The reaction product of such complete removal is called a completely deprotected radioactive compound. Correspondingly, the incomplete removal of protecting groups from a radioactive compound (also called incomplete deprotection or partial deprotection) is defined as the removal of at least one protecting group contained in a radioactive compound having multiple protecting groups, but not all protecting groups. The reaction product of such incomplete removal is called a partially deprotected radioactive compound.

[0084] In one preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the hydrolysis comprises the removal of a protecting group from the radioactive compound, wherein the radioactive compound independently has a plurality of protecting groups selected from the group consisting of tert-butylcarbamate (t-Boc), tert-butyl ester (OtBu), benzyl ester (BzO), benzylidene, tetrahydropyranyl ether (THP), acetal, trityl (Trt), and methoxymethyl ether (MOM), preferably wherein each protecting group is tert-butylcarbamate (t-Boc). Preferably, the yield of the corresponding fully deprotected radioactive compound is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%. Preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected in the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is performed at a temperature selected in the range of 30°C to a maximum of 55°C, and the heating time is selected in the range of 1 minute to a maximum of 10 minutes.

[0085] In one more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the hydrolysis comprises the removal of a protecting group from the radioactive compound. - Here, the degree of radiolysis during the hydrolysis is less than 5%, preferably less than 3%; and / or - Here, the yield of the corresponding fully deprotected radioactive compound is at least 30%, preferably at least 35%; and / or - Here, the hydrolysis occurs in an aqueous solution at a pH of less than 7, preferably less than 6; and / or - Here, the mixture includes phosphoric acid; and / or - Here, the radioactive compound independently has a plurality of protecting groups selected from the group consisting of tert-butylcarbamate (t-Boc), tert-butyl ester (OtBu), benzyl ester (BzO), benzylidene, tetrahydropyranyl ether (THP), acetal, trityl (Trt), and methoxymethyl ether (MOM), preferably where each protecting group is tert-butylcarbamate (t-Boc); and / or - Here, the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes; and / or - Herein, the heating of the mixture is at a temperature selected from the following ranges: 30°C up to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C.

[0086] A side reaction in the removal of a protecting group from a radioactive compound is defined as a chemical reaction of the radioactive compound that yields a side reaction product, where the side reaction product is not the radioactive compound, a partially deprotected radioactive compound equivalent to the removal, or a fully deprotected radioactive compound equivalent to the removal. For example, isomerization may be considered a side reaction of protecting group removal. In this specification, "equivalent to the removal" should be understood to mean that the side reaction may also be the removal of another type of protecting group. For example, the removal of a tetrahydropyranyl ether (THP) protecting group may be considered a side reaction of the removal of a tert-butylcarbamate (t-Boc) protecting group. Directly linked to the above definition, a side reaction product in the removal of a protecting group from a radioactive compound is defined as a compound produced during the side reaction of the removal, where the side reaction product is not the radioactive compound, a partially deprotected radioactive compound equivalent to the removal, or a fully deprotected radioactive compound equivalent to the removal.

[0087] In one preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the hydrolysis comprises the removal of a protecting group from the radioactive compound, wherein the yields of various by-reaction products of the removal of the protecting group are 15%, 14.5%, 14%, 13.5%, 13%, 12.5%, and 12%. The percentages are less than %, 11.5%, 11%, 10.5%, 10%, 9.5%, 9%, 8.5%, 8%, 7.5%, 7%, 6.5%, 6%, 5.5%, 5%, 4.8%, 4.6%, 4.4%, 4.2%, 4%, 3.8%, 3.6%, 3.4%, 3.2%, 3%, 2.8%, 2.6%, 2.4%, 2.2%, 2%, 1.8%, 1.6%, 1.4%, 1.2%, 1%, 0.8%, 0.6%, 0.4%, 0.2%, and 0.1%. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is performed at a temperature selected in the range of 30°C to a maximum of 55°C, and the heating time is selected in the range of 1 minute to a maximum of 10 minutes.

[0088] In the context of deprotection, unless explicitly defined otherwise, "deprotection yield" and "deprotection reaction yield" refer to the ratio of the number of fully deprotected radioactive compounds to the number of protected and partially deprotected radioactive compounds, whereas "yield of fully deprotected radioactive compounds" refers to the yield of all-total deprotected radioactive compounds as defined above. In other words, if "deprotection" is used as a noun modifier of "yield," side reactions are not taken into account. If "deprotection" is not used as a noun modifier, it refers to the yield as defined above.

[0089] In Examples 1 and 2, the method according to the present invention is as follows: the chemical reaction occurs during heating, Boc2-[ 131This involves the deprotection of [I]SGMIB, i.e., the removal of the Boc protecting group. Under the conditions described therein, almost complete deprotection was achieved (the yield of the corresponding completely deprotected radioactive compound was higher than 90%), whereas by-products were formed in yields ranging from only 3 to 12%. These findings are exceptional and in contrast to methods for deprotection disclosed in the art, for the reason that typically reported yields of completely deprotected reaction products are around 30%. In addition, the level of by-products in methods for deprotection reported in the art is around 25%.

[0090] In one preferred embodiment, the following method according to the present invention is provided, wherein the chemical reaction comprises alkylation of the radioactive compound, preferably, wherein the alkylation occurs during heating. Alkylation preferably means a nucleophilic substitution reaction or an addition reaction, wherein the radioactive compound acts either as a nucleophile or an electrophile to obtain a net addition of an alkyl group to the radioactive compound. The alkyl group is preferably selected from the group consisting of branched, unbranched, and cyclic C1-C8 alkyl groups, more preferably methyl, ethyl, n-propyl, iso-propyl, c-propyl, n-butyl, sec-butyl, tert-butyl, iso-butyl, and c-butyl. The alkyl group may optionally be substituted. The reaction product obtained by alkylation of the radioactive compound is called an alkylated radioactive compound. It is preferable that the alkylation does not involve the use of an alkaline solution.

[0091] In one more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the alkylation of the radioactive compound, wherein the alkylation occurs during heating, wherein the alkylation has a high activation barrier, and preferably, wherein the solid phase is a facilitator for the alkylation.

[0092] In the above preferred embodiments, the degree of radiolysis during alkylation is preferably lower than 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1%. Preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected in the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C, and the heating time is selected in the range of 1 minute to a maximum of 10 minutes.

[0093] In the above preferred embodiments, the yield of the alkylated radioactive compound is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%. Preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected in the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is performed at a temperature selected in the range of 30°C to a maximum of 55°C, and the heating time is selected in the range of 1 minute to a maximum of 10 minutes.

[0094] In one most preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the alkylation of the radioactive compound, wherein the alkylation occurs during heating, wherein the degree of radiolysis during the alkylation is less than 5%, and wherein the yield of the alkylated radioactive compound is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, The yields are 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%, preferably where the degree of radiolysis during alkylation is less than 3%, and where the yield of the alkylated radioactive compound is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 10 minutes.

[0095] In one most preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the alkylation of the radioactive compound, wherein the alkylation occurs during heating, wherein the degree of radiolysis during the alkylation is less than 5%, and wherein the yield of the alkylation reaction product is at least 30%, preferably, wherein the degree of radiolysis during the alkylation is less than 3%, and wherein the yield of the alkylation reaction product is at least 30%. The heating rate is at least 35%, where the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes, and the heating of the mixture is at a temperature selected from the following ranges: 30°C to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, the heating of the mixture is at a temperature selected from the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected from the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 10 minutes, or the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 5 minutes. Most preferably, the heating of the mixture is at a temperature selected from a range of 30°C to a maximum of 55°C, and the heating time is selected from a range of 1 minute to a maximum of 10 minutes.

[0096] In one most preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises alkylation of the radioactive compound, wherein the alkylation occurs during heating, wherein the yield of the alkylation reaction product is at least 30%, preferably, wherein the yield of the alkylation reaction product is at least 35%, wherein the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes, and the heating of the mixture is at a temperature selected from the following ranges: 30°C to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected within the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 10 minutes, or the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 5 minutes. Most preferably, the heating of the mixture is to a temperature selected within the range of 30°C to a maximum of 55°C, and the heating time is selected within the range of 1 minute to a maximum of 10 minutes.

[0097] Adhesion to a solid phase In one preferred embodiment, the present invention provides a method in which, upon contact of the mixture with the solid phase, no adhesion of the radioactive compound to the solid phase occurs. In other words, as a result of the contact, neither chemiadsorption nor physiadsorption occurs between the radioactive compound and the solid phase. In this embodiment, the radioactive compound reacts within the bulk of the mixture, i.e., no bond is formed with the solid phase. Preferably, the solid phase is a facilitator.

[0098] In another preferred embodiment, the following method according to the present invention is provided, in which the mixture is brought into contact with the solid phase, and the radioactive compound adheres to the solid phase. Preferably, the radioactive compound adheres to the solid phase in step (b). In the context of this embodiment, the adhesion preferably results in a non-covalent bond formed by the adsorption of the radioactive compound to the solid phase. In other words, in this preferred embodiment, the solid phase functions as a facilitator instead of a catalyst in step (b) when the rate of the chemical reaction of the radioactive compound is increased.

[0099] In one more preferred embodiment, a method according to the present invention is provided, wherein (a) the mixture is brought into contact with the solid phase, causing the radioactive compound to adhere to the solid phase, wherein at the end of step (b), the radioactive compound remains adhered to the solid phase.

[0100] The adhesion of the radioactive compound to the solid phase in the method according to the embodiments described above has the advantage that the solid phase to which the radioactive compound is attached can react further, and the need for purification between multiple reaction steps is minimized. For example, Boc2-[ 131 [I] Deprotection of SGMIB results in a completely deprotected SGMIB adhering to the Sep-Pak tC18 contained within a standard SPE cartridge. This cartridge may be used for further reactions.

[0101] In this regard, one preferred embodiment provides a method according to the present invention, wherein (a) the mixture is brought into contact with the solid phase, causing the radioactive compound to adhere to the solid phase, wherein at the end of step (b), the radioactive compound remains adhered to the solid phase, and the method includes a step (b') at the end of step (b) to carry out a further chemical reaction of the radioactive compound. As skilled in the art will understand, it is preferable that no purification step is required between step (b) and step (b') in the method according to the present invention. It is preferable that at the end of step (b'), the radioactive compound remains adhered to the solid phase. In this context, the further chemical reaction should be interpreted as a chemical reaction that occurs after step (b), wherein carrying out the further chemical reaction is included in the method for carrying out the chemical reaction in the present invention. This is an advantage of the method of the present invention, because it becomes possible to directly carry out further reactions with the radioactive compound that is still attached to the solid phase obtained in this way, and therefore there is no need to purify the compound for the purpose of carrying out these further reactions.

[0102] The method according to the present invention should be designed to allow for the removal of the radioactive compound attached to the solid phase during or after the process. For example, this would be necessary to carry out further chemical reactions that cannot be performed while the radioactive compound remains attached to the solid phase.

[0103] In one preferred embodiment, a method according to the present invention is provided, wherein (a) the mixture is brought into contact with the solid phase, causing the radioactive compound to adhere to the solid phase, and the method further includes step (c) desorbing the radioactive compound from the solid phase. Preferably, step (c) is carried out after step (b). More preferably, step (c) is carried out after step (b').

[0104] In the context of this application, the attachment and detachment of the radioactive compound should not be interpreted narrowly. If it is defined that the attachment of the radioactive compound to the solid phase occurs by contacting the mixture with the solid phase, and that the compound remains attached to the solid phase at the end of step (b) and / or step (b'), then this should be understood to include the fact that various (desired) radioactive reaction products of the radioactive compound, including various (desired) radioactive intermediates, remain attached to the solid phase. For example, if deprotection of the radioactive compound occurs in step (b) of heating the mixture, and that the radioactive compound remains attached to the solid phase at the end of step (b), then it should be understood that the corresponding deprotected radioactive compound remains attached to the solid phase. Similarly, the desorption of the radioactive compound includes (a) the contact with the solid phase and / or (b) the heating of the mixture and / or (b') the desorption of various desired reaction products of the chemical reaction that occurred during the execution of the further chemical reaction, or the steps thereof. It is preferable that the desired reaction product is a radioactive compound.

[0105] In the context of the embodiments described above, the eluent is defined as a liquid used to separate the mixture from the solid phase in step (c). In one more preferred embodiment, a method according to the present invention is provided, wherein (a) the mixture is brought into contact with the solid phase, causing the radioactive compound to adhere to the solid phase, wherein the method comprises step (c), by bringing the solid phase into contact with the eluent, thereby desorbing the radioactive compound from the solid phase, wherein the eluent is selected from the group consisting of aqueous solutions, organic solvents, or mixtures thereof, preferably wherein the organic solvent is a mixture of water and ethanol, more preferably wherein the organic solvent is ethanol. Preferably, step (c) is carried out after step (b). More preferably, step (c) is carried out after step (b').

[0106] The mixture of water and ethanol is preferably selected from the group consisting of the following proportions of ethanol in the water: 0.5% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight Weight%, 21% by weight, 22% by weight, 23% by weight, 24% by weight, 25% by weight, 26% by weight, 27% by weight, 28% by weight, 29% by weight, 30% by weight, 31% by weight, 32% by weight, 33% by weight , 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight Amount%, 48% by weight, 49% by weight, 50% by weight, 51% by weight, 52% by weight, 53% by weight, 54% by weight, 55% by weight, 56% by weight, 57% by weight, 58% by weight, 59% by weight, 60% by weight, 61% by weight, 62% by weight, 63% by weight, 64% by weight, 65% by weight, 66% by weight, 67% by weight, 68% by weight, 69% by weight, 70% by weight, 71% by weight, 72% by weight, 73% by weight, 74% by weight Weight%, 75% by weight, 76% by weight, 77% by weight, 78% by weight, 79% by weight, 80% by weight, 81% by weight, 82% by weight, 83% by weight, 84% by weight, 85% by weight, 86% by weight, 87% by weight, 88% by weight, 89% by weight, 90% by weight, 91% by weight, 92% by weight, 93% by weight, 94% by weight, 95% by weight, 96% by weight, 97% by weight, 98% by weight, 99% by weight, or 99.5% by weight.

[0107] radioactive compound In the method according to the present invention, the radioactive compound does not contain fluorine-18.

[0108] In one more preferred embodiment, a method according to the present invention is provided, wherein the radioactive compound includes a radionuclide selected from the group consisting of α-radiators and β-radiators, preferably, wherein the radionuclide is selected from the group consisting of hydrogen-3, astatine-211, carbon-11, carbon-14, bromine-76, iodine-123, iodine-124, iodine-125, iodine-131, phosphorus-32, and sulfur-35, most preferably, wherein the radionuclide is selected from the group consisting of astatine-211, iodine-123, iodine-124, and iodine-131. The radionuclide used is not fluorine-18.

[0109] In one preferred embodiment, a method according to the present invention is provided, wherein the radioactive compound comprises a radionuclide that is both a β-radiator and a γ-radiator, preferably wherein the radionuclide is iodine-131.

[0110] In one preferred embodiment, a method according to the present invention is provided, wherein the radioactive compound comprises one and no more than two radionuclides, preferably wherein the radionuclides are iodine-131.

[0111] In one preferred embodiment, the following method according to the present invention is provided, wherein the radionuclides contained in the radioactive compound have atomic numbers from 11 to a maximum of 118, preferably from 19 to a maximum of 118, and more preferably from 37 to a maximum of 118.

[0112] In one preferred embodiment, the expression "wherein the radioactive compound does not contain fluorine-18" is replaced with: "wherein the radioactive compound, the various radionuclides included are selected from the group consisting of hydrogen-3, astatine-211, carbon-11, carbon-14, bromine-76, iodine-123, iodine-124, iodine-125, iodine-131, phosphorus-32, and sulfur-35." In other words, the method in this preferred embodiment can be described as: a method for carrying out a chemical reaction of a radioactive compound contained in a mixture, wherein the method includes (a) contacting the mixture with a solid phase, and subsequently (b) heating the mixture to a temperature selected in the range of 30°C to a maximum of 150°C, wherein steps (a) and (b) do not involve contacting the solid phase with an alkaline solution, wherein the chemical reaction does not result in the formation of new bonds on the radionuclides contained in the radioactive compound, wherein the various radionuclides contained in the radioactive compound are selected from the group consisting of hydrogen-3, astatine-211, carbon-11, carbon-14, bromine-76, iodine-123, iodine-124, iodine-125, iodine-131, phosphorus-32, and sulfur-35.

[0113] In view of the above, the method according to the embodiment described above can therefore be expressed as follows: a method for carrying out a chemical reaction of a radioactive compound contained in a mixture, wherein the method comprises (a) a step of contacting the mixture with a solid phase, and subsequently (b) a step of heating the mixture to a temperature selected in the range of 30°C to a maximum of 150°C, wherein all solutions in contact with the solid phase during steps (a) and (b) are neutral or acidic solutions, wherein the chemical reaction does not result in the formation of new bonds on the radionuclides contained in the radioactive compound, wherein the various radionuclides contained in the radioactive compound are selected from the group consisting of hydrogen-3, astatine-211, carbon-11, carbon-14, bromine-76, iodine-123, iodine-124, iodine-125, iodine-131, phosphorus-32, and sulfur-35.

[0114] In view of the above, the method according to the embodiment described above can therefore be expressed as follows: a method for carrying out a chemical reaction of a radioactive compound contained in a mixture, wherein the method comprises (a) a step of contacting the mixture with a solid phase, and subsequently (b) a step of heating the mixture to a temperature selected in the range of 30°C to a maximum of 150°C, wherein steps (a) and (b) do not involve contacting the solid phase with an alkaline solution, wherein the chemical reaction is a post-labeling reaction, wherein the various radionuclides contained in the radioactive compound are selected from the group consisting of hydrogen-3, astatine-211, carbon-11, carbon-14, bromine-76, iodine-123, iodine-124, iodine-125, iodine-131, phosphorus-32, and sulfur-35.

[0115] In view of the above, the method according to the foregoing embodiment can thus be stated as follows: a method for carrying out a chemical reaction of a radioactive compound contained in a mixture, wherein the method comprises: (a) contacting the mixture with a solid phase, followed by (b) heating the mixture to a temperature selected in the range from 30°C to a maximum of 150°C, wherein, during steps (a) and (b), all solutions contacting the solid phase are neutral or acidic solutions, wherein the chemical reaction is a post-labeling reaction, and wherein the various radionuclides contained in the radioactive compound are selected from the group consisting of hydrogen-3, astatine-211, carbon-11, carbon-14, bromine-76, iodine-123, iodine-124, iodine-125, iodine-131, phosphorus-32, and sulfur-35.

[0116] In one preferred embodiment, a method according to the present invention is provided as follows, wherein the radioactive compound is selected from the group consisting of: N-succinimidyl 4-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3- 131 I]iodobenzoate (Boc2- 131 I]SGMIB), N-succinimidyl 4-(1-tert-butoxycarbonylguanidino)methyl-3- 131 I]iodobenzoate (Boc- 131 I]SGMIB), N-succinimidyl 3-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3- 131 I]iodobenzoate (iso-Boc2- 131 I]SGMIB), N-succinimidyl 3-(1-tert-butoxycarbonylguanidinomethyl-3- 131 I]iodobenzoate (iso-Boc- 131 I]SGMIB)), N,N'-bis(tert-butoxycarbonyl)-3- 123 I]iodobenzylguanidine (Boc2- 131 I]MIBG), N-tert-butoxycarbonyl-3- 123I] Iodobenzylguanidine (Boc-[ 131 I]MIBG), (2R,3S)-2-[(2-[ 123 I] Iodophenoxy)phenylmethyl]-N-tert-butoxycarbonyl-morpholine (Boc-[ 123 I]I-NKJ64), and (S)-2-N-tert-butoxycarbonyl-3-(4-[ 125 I] Iodophenyl)propanoate (Boc-[ 125 I]I-Phe). Preferably, here the radioactive compound is N-succinimidyl-4-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3-[ 131 I] Iodobenzoate (Boc2-[ 131 I)SGMIB)

[0117] As is obvious to those skilled in this field, Boc2-[ 131 The two tert-butoxycarbonyl (Boc, or tert-Boc) groups contained in [I]SGMIB are protecting groups. In the context of the deprotection reaction defined above, Boc2-[ 131 By completely deprotecting I]SGMIB, N-succinimidyl-4-guanidinomethyl-3-[ 131 I] Iodobenzoate ([ 131 I]SGMIB) can be obtained. Boc2-[ 131 If the deprotection of I]SGMIB is incomplete, i.e., partial, then N-succinimidyl-4-(1-tert-butoxycarbonylguanidino)methyl-3-[ 131 I] Iodobenzoate (1'-Boc-[ 131 I]SGMIB), or N-succinimidyl-4-(2-tert-butoxycarbonylguanidino)methyl-3-[ 131 I] Iodobenzoate (2'-Boc-[ 131 I]SGMIB) can be obtained, but all of these are Boc-[ 131 I] It can be expressed as SGMIB.

[0118] In one more preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during the heating, wherein the hydrolysis comprises the removal of a protecting group from the radioactive compound, wherein the radioactive compound is N-succinimidyl-4-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3-[ 131 I] Iodobenzoate (Boc2-[ 131 I]SGMIB) - Here, the degree of radiolysis during the hydrolysis is less than 5%, preferably less than 3%; and / or - Here, the hydrolysis occurs in an aqueous solution at a pH of less than 7, preferably less than 6, and preferably, here the aqueous solution contains phosphoric acid; and / or - Here, N-succinimidyl-4-guanidinomethyl-3-[ 131 I] Iodobenzoate ([ 131 I)SGMIB) yield is at least 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, or 97.5%; and / or - Here, the heating time is selected within a range of 1 minute to a maximum of 10 minutes. More preferably, the heating time is selected within a range of 1 minute to a maximum of 5 minutes.

[0119] In one most preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the hydrolysis comprises the removal of a protecting group from the radioactive compound, wherein the radioactive compound is N-succinimidyl-4-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3-[ 131I] Iodobenzoate (Boc2-[ 131 I]SGMIB) - Here, the degree of radiolysis during the hydrolysis is less than 5%, preferably less than 3%; and / or - Here, the hydrolysis occurs in an aqueous solution at a pH of less than 7, preferably less than 6, and preferably, here the aqueous solution contains phosphoric acid; and / or - Here, N-succinimidyl-4-guanidinomethyl-3-[ 131 I] Iodobenzoate ([ 131 The yield of [SGMIB] is at least 30%, preferably at least 35%; and / or - Here, the heating time is in the range of 1 minute to a maximum of 10 minutes, more preferably in the range of 1 minute to a maximum of 5 minutes; and / or - Herein, the heating of the mixture is to a temperature selected from the following ranges: 30°C up to 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, herein, the heating of the mixture is to a temperature selected from the range of 30°C up to 55°C.

[0120] In one more preferred embodiment, a method according to the above-described embodiment is provided, wherein the mixture is brought into contact with the solid phase, causing the radioactive compound to adhere to the solid phase, and further comprising step (c) desorbing the radioactive compound from the solid phase using an eluent, wherein the eluent is selected from the group consisting of aqueous solutions, organic solvents, or mixtures thereof, preferably wherein the solvent is a mixture of water and ethanol, more preferably wherein the solvent is ethanol. In these preferred embodiments, the solid phase is preferably a facilitator.

[0121] In one preferred embodiment, a method according to the present invention is provided, wherein the chemical reaction comprises the hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the hydrolysis comprises the removal of a protecting group from the radioactive compound, wherein the radioactive compound is N-succinimidyl-4-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3-[ 131 I] Iodobenzoate (Boc2-[ 131 I]SGMIB) where N-succinimidyl-4-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3-[(131)I]iodobenzoate (Boc2-[ 131 During heating, N-succinimidyl-4-guanidinomethyl-3-[(131)I]iodobenzoate ([ 131 I) is converted to SGMIB), where the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C. Preferably, the heating time is selected in the range of 1 minute to a maximum of 5 or 10 minutes. More preferably, the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 55°C, and the heating time is selected in the range of 1 minute to a maximum of 10 minutes.

[0122] In one preferred embodiment, a method according to the present invention is provided, wherein the radioactivity intensity of the radioactive compound is between 0.1 curie and a maximum of 100 curie, 0.5 curie and a maximum of 100 curie, 1 curie and a maximum of 100 curie, 2 curie and a maximum of 100 curie, 3 curie and a maximum of 100 curie, 4 curie and a maximum of 100 curie, 5 curie and a maximum of 100 curie, and 10 curie and a maximum of 100 curie. The radioactivity intensity of the radioactive compound is preferably measured at the end of step (b) included in the method according to the present invention.

[0123] Solid phase and composition In one preferred embodiment, the following method according to the present invention is provided, wherein the solid phase is a silica or polymer-based solid phase, preferably selected from the group consisting of Sep-Pak tC18, Step-Pak C18, Oasis HLB, Oasis MCX, Oasis MAX, and Sephadex LH-20, and preferably, wherein the solid phase is Sep-Pak tC18.

[0124] In one preferred embodiment, a method according to the present invention is provided, wherein the solid phase is a silica or polymer-based solid phase, and the solid phase is a facilitator for the reaction.

[0125] In the context of this application, a (chemical) reaction in which a solid phase functions as a facilitator is referred to as a (chemical) reaction facilitated by the solid phase.

[0126] In one preferred embodiment, a method according to the present invention is provided, in which the solid phase and the mixture are incorporated into a cartridge, preferably a solid-phase extraction (SPE) cartridge. As is well known to those skilled in the art, SPE cartridges containing the solid phases specified above are available on the market.

[0127] In one more preferred embodiment, a method according to the present invention is provided, wherein the solid phase and the mixture are incorporated into a cartridge, preferably a solid-phase extraction (SPE) cartridge, wherein the cartridge is discardable, preferably single-use. A discardable cartridge is defined in the method according to the present invention as a cartridge that can be used for only a limited number of repetitions, wherein the limited number of repetitions is preferably 100, 50, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1. Notwithstanding this theory, using a discardable cartridge for a greater number of repetitions may reduce the yield of the reaction product desired in the chemical reaction according to the present invention.

[0128] In one more preferred embodiment, a method according to the present invention is provided, wherein the solid phase and the mixture are incorporated into a cartridge, preferably a solid-phase extraction (SPE) cartridge, wherein the cartridge is for single use only. A single-use cartridge is defined as a cartridge that can be used only once in a single repetition in the method according to the present invention as described above.

[0129] In one preferred embodiment, a method according to the present invention is provided, wherein the method is automated. In the context of the present invention, a method for carrying out a chemical reaction is automated if the following conditions are met: (a) the contact with the solid phase, and / or (b) the heating of the mixture, and / or (c) the desorption of the radioactive compound, and / or (d) the attachment of the biological residue does not require direct manipulation by a human operator. Preferably, direct manipulation means manipulating or holding a receptor containing the mixture containing the radioactive compound, and / or manually adjusting the reaction conditions in (a) and / or (b) and / or (c) and / or (d), such as temperature.

[0130] The method according to the present invention preferably involves the use of a device or system according to the present invention as defined below, wherein (b) the heating of the mixture in the method is achieved by the powering of the heating means included in the device or system. Preferably, the method according to the present invention is carried out using a system according to the present invention as defined in the context of a fifth aspect of the present invention.

[0131] As will be obvious to those skilled in the art, whenever a device or system in the present invention is used in a method according to the present invention as described in this specification or other disclosures in the context of this application: - The mixture described in the context of a device or system according to the present invention is the mixture containing a radioactive compound as described in the context of the method according to the present invention; - (b) in the method described above, the heating of the mixture is achieved by the focus of the heating means included in the device or system; - Preferably, the chemical reaction is carried out in the chemical reaction vessel contained within the stem, as defined in the context of the method according to the present invention; - Preferably, the solid phase in step (a) of the method is the solid phase included in the system.

[0132] In this regard, all selections and embodiments disclosed in the context of the methods according to the present invention can be applied to the devices or systems of the present invention with modifications as necessary. Furthermore, all preferred embodiments and definitions relating to the devices or systems of the present invention should be interpreted as preferred embodiments and definitions relating to the methods according to the present invention, including the use of such devices or systems.

[0133] Specifically, as an example, in one preferred embodiment, a method according to the present invention is provided, which includes the use of a system or device according to the present invention, wherein the chemical reaction vessel included in the system is an SPE cartridge.

[0134] biological moiety In one preferred embodiment, a method according to the present invention is provided, wherein the mixture is brought into contact with the solid phase, thereby causing the radioactive compound to adhere to the solid phase, wherein the chemical reaction comprises hydrolysis of the radioactive compound, wherein the hydrolysis occurs during heating, wherein the hydrolysis comprises the removal of a protecting group from the radioactive compound, wherein the method further comprises step (c) desorbing the radioactive compound from the solid phase, wherein the method comprises step (d) attaching a biological residue to the deprotected radioactive compound obtained at the end of step (c), wherein the attachment provides a radiolabeled biological residue. In the context of this application, a method according to this embodiment is referred to in the present invention as a method for attaching a biological residue. The biological residue is preferably a polymer of lipids, monosaccharides, or amino acids, more preferably a polymer of amino acids.

[0135] In one preferred embodiment, the present invention provides a method for attaching a biological residue, wherein the biological residue is a peptide, a protein backbone, or an antibody or a fragment thereof, preferably wherein the biological residue is a diagnostic and / or therapeutic compound.

[0136] Preferred peptides usable as biological residues in the context of this application are selected from the group consisting of: FAPI, PSMA-617, PSMA-11, Substance P, somatostatin analogs, gastrin-releasing peptide receptor ligands, and ECL1i.

[0137] Suitable protein backbones usable as biological residues in the context of this application are selected from the group consisting of: Affibody (including ZHER2:342 and ABY-025), Affitin, Knottin, and Darpin.

[0138] In one preferred embodiment, the present invention provides a method for attaching a biological residue, wherein the biological residue is an antibody or a fragment thereof, preferably wherein the antibody or fragment thereof is a compound for diagnostic and / or therapeutic purposes.

[0139] Antibodies refer to polyclonal antibodies, monoclonal antibodies, humanized antibodies, single-chain antibodies, and their fragments, such as Fab, F(ab)2, Fv, Fab, F(ab)2, scFv, minibody, bispecific antibody (biabody), scFv-Fc, and other fragments that retain the antigen-binding function of the parent antibody. Thus, antibodies may also refer to constructs containing an antigen-binding portion within an immunoglobulin or glycoprotein or a fragment or part thereof, or a denatured immunoglobulin-like framework, or a construct containing an antigen-binding portion within a non-immunoglobulin-like framework or backbone.

[0140] Preferred antibodies or fragments thereof that can be used as biological residues in the context of this application are selected from the group consisting of: FF-21101, h11B6, CYT-500, chimeric G250, B-B4, Mu11-1F4, BC-8, trastuzumab, pertuzumab, cetuximab, ibritumobab, tositumomab, rituximab, gylenetuzumab, lintuzumab, F16SIP, huA33, J591, 81C6, CC49-deltaCH2, VRC01, Hu3S193, A33, MN-14, B3, BW250 / 183, Lym-1, TNT-1 / B, 8H9, Diabody T84.66, huLL2, chimeric T84.66, MAB-145, huM195, CC49, daclizumab, hPAM4, BU-12, 3F8, amatsuximab, atezolizumab, ombrutamab, IAB22M2X CD8 minibody, FPI-1434, BC8-B10, F(ab)2 MX35, 9.2.27, epratutumab, BAY 861903, and BAY 2315158.

[0141] A monoclonal antibody refers to an antibody composition having a homogeneous antibody population. This term is not limited to the species or origin of the antibody, nor is it limited to the method by which it was produced. This term includes whole immunoglobulins, as well as fragments and other components that retain the antigen-binding function of the antibody. A polyclonal antibody refers to an antibody composition having a heterogeneous antibody population.

[0142] Therapeutic compounds are compounds used to treat, induce remission, prevent, and / or delay a disease or condition. Diagnostic compounds are compounds used to detect a disease or condition in an individual. In this context, the antibody or fragment thereof can bind to an antigen associated with the disease or condition. It is preferable that the antigen is expressed in cells associated with the disease or condition.

[0143] The disease is preferably cancer, more preferably a solid tumor, and most preferably the solid tumor is selected from the group consisting of breast cancer, ovarian cancer, gastric cancer, multiple myeloma, and lymphoma. Separately from these, the cancer may be a hematological cancer.

[0144] In one preferred embodiment, the present invention provides a method for attaching a biological residue, wherein the biological residue is an antibody or a fragment thereof, wherein the antibody or fragment thereof is a diagnostic and / or therapeutic compound, wherein the diagnostic and / or therapeutic compound targets an antigen expressed in a cell and / or present on the surface of a cell.

[0145] Antigens expressed within tumor cells are tumor-specific antigens or cancer cell-specific antigens that are specifically generated or specifically and / or produced in large quantities on or on the surface of tumor cells or cancer cells, respectively, but which are preferably not present at all or expressed at relatively low concentrations or densities on or on the surface of normal healthy cells. When these tumor-specific or cancer cell-specific antigens are bound to antigens or VHH or fragments thereof used as biological residues in the method for attaching biological residues in the present invention, the corresponding tumor or cancer cells on which the antigen is expressed are killed or at least their growth is inhibited, suppressed, or reduced via a radiotoxicity mechanism, or the corresponding tumor or cancer cells on which the antigen is expressed can be radiolabeled.

[0146] Appropriate tumor-specific or cancer cell-specific target molecules are readily available to experts in the field from existing literature or patent databases and include, but are not limited to, various proteins, tissue differentiation antigens, mutant protein antigens, oncogenic virus antigens, cancer / testicular antigens, oncoebrional antigens, and vascular or stromal-specific antigens produced by tumor cells with abnormal structures due to mutations, including abnormal products of the ras and p53 genes. Examples of specific tumor antigens include, but are not limited to, CTAG1B, MAGEA1, the enzyme tyrosinase, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), EBV and HPV, abnormally structured cell surface glycolipids and glycoproteins, HER2, EGFR, PSMA, FAP, CD33, CD45, tenacin-C, IGF-1R, SSR2, and their variants.

[0147] Therefore, the method for attaching biological residues in the present invention provides a method for obtaining radiolabeled diagnostic and / or therapeutic compounds for tumor cells, wherein the biological residue is an antibody or a fragment thereof, wherein the antibody or fragment thereof is a diagnostic and / or therapeutic compound, wherein the diagnostic and / or therapeutic compound targets an antigen expressed in tumor cells and / or is present on the surface of tumor cells.

[0148] In the embodiments described above, the antigen is preferably HER2, and therefore the tumor cells are HER2-positive tumor cells.

[0149] In other words, in some embodiments, the reaction products of the method for attaching biological residues according to the present invention can kill tumor cells or cancer cells expressing antigens, whereas antibodies, VHHs, or fragments thereof can be used as biological residues in the method, or the growth and / or proliferation of such tumor cells or cancer cells can be reduced or slowed.

[0150] In some embodiments, the antibody, VHH, or fragment thereof used as the biological residue in the method for attaching the biological residue according to the present invention is monovalent. In this specification, monovalent means that the antibody, VHH, or fragment thereof has only one binding site for a given antigen as defined above.

[0151] It is preferable that the antigen expressed in tumor cells is HER2. Therefore, in some embodiments, the antibody, VHH, or fragment thereof used in the method for attaching biological residues in the present invention binds specifically to HER2.

[0152] In one preferred embodiment, the method according to the above-described embodiment is provided, wherein the antibody or fragment thereof is a heavy chain variable domain derived from a heavy chain antibody (VHH), and preferably, wherein the heavy chain antibody (VHH) or fragment thereof has at least 80% amino acid identity or has the amino acid sequence number 7 or number 8.

[0153] An antibody fragment may be the heavy chain variable domain of an antibody or a fragment thereof. When used herein, the heavy chain variable domain or fragment thereof has the following meanings: (i) the heavy chain variable domain of a heavy chain antibody that inherently lacks a light chain (represented herein as VHH), non-limitingly including, for example, the heavy chain variable domain of a heavy chain antibody from a camelid or shark; or (ii) the heavy chain variable domain of a conventional quadruple-chain antibody or various fragments thereof, non-limitingly including, for example, one or more amino acid residues (i.e., small peptides); they are particularly suitable for binding to tumor antigens or antigens present on cancer cells, and may be present in and / or incorporated into VHH as disclosed herein (may be based on and / or derived from the CDR sequence of VHH as disclosed herein). It is preferable that the antibody heavy chain variable domain or fragment thereof is VHH or a fragment thereof.

[0154] The amino acid sequence and structure of the heavy chain variable domain of an antibody can be considered to consist of four framework regions, or PRs, (but are not limited to these), which are referred to in the art and herein as "framework region 1" or "FR1," "framework region 2" or "FR2," "framework region 3" or "FR3," and "framework region 4" or "FR4," respectively. These framework regions are interrupted by three complementarity determining regions, or "CDRs," which are referred to in the art as "complementarity determining region 1" or "CDR1," "complementarity determining region 2" or "CDR2," and "complementarity determining region 3" or "CDR3," respectively.

[0155] As used herein, the term “complementarity-determining region,” or “CDR,” in the context of antibodies refers to a variable region in either the heavy (H) chain or the light (L) chain (also abbreviated as VH and VL, respectively), which contains an amino acid sequence capable of specifically binding to an antigen target. These CDR regions carry the fundamental specificity of the antibody for a particular antigenic determinant structure. Such regions are also called “hypervariable regions.” While CDRs represent discontinuous stretches of amino acids within a variable region, the positions of these key amino acid sequences within the variable heavy and light chain regions have been found to be similar to their positions within the amino acid sequence of the variable chain, regardless of species. The variable heavy and light chains of all canonical antibodies each have three discontinuous CDR regions (named L1, L2, L3, H1, H2, H3) for the light chain (L) and heavy chain (H), respectively.

[0156] In some embodiments, as will be further described below, the total number of amino acid residues in the heavy chain variable domain (including VHH) of the antibody can be in the range of 110 to 130, preferably 112 to 115, and most preferably 113. However, it should be noted that there are no particular limitations on the length and / or size of a portion, fragment, or analog of the heavy chain variable domain of the antibody, as long as such portion, fragment, or analog retains at least a portion of the functional activity and / or the binding specificity of at least a portion of the heavy chain variable domain of the original antibody from which those portion, fragment, or analog originates. A portion, fragment, or analog that retains at least a portion of the functional activity and / or the binding specificity of at least a portion of the heavy chain variable domain of the original antibody from which those portion, fragment, or analog originate is also referred to herein as a “functional fragment” of the heavy chain variable domain. It is preferable that the fragment of the heavy chain variable domain or the fragment of the VHH are, respectively, a functional fragment of the heavy chain variable domain or a functional fragment of the VHH.

[0157] This disclosure provides stretches of numerous amino acid residues particularly suitable for binding to tumor antigens or cancer cell antigens, including, but not limited to, HER2. These stretches of amino acid residues may be present in and / or incorporated into VHHs used as biological residues in the methods for attaching biological residues in the present invention, in particular, such that they form (part of) the antigen-binding sites of the VHH. Since these stretches of amino acid residues were originally formed as CDR sequences of antibodies (or may be based on and / or derived from such CDR sequences), they will also be referred to herein in general terms as “CDR sequences” (e.g., CDR1 sequence, CDR2 sequence, and CDR3 sequence, respectively).

[0158] Therefore, in specific but non-limiting embodiments, the VHH used as a biological residue in the method for attaching a biological residue according to the present invention includes at least one amino acid sequence selected from the group consisting of the CDR1, CDR2, and CDR3 sequences described herein. In some embodiments, the VHH may include at least one antigen-binding site, where the antigen-binding site includes at least one combination of the CDR1, CDR2, and CDR3 sequences described herein.

[0159] VHHs or fragments thereof having one of these CDR sequence combinations, using biological residues in the method for attaching biological residues according to the present invention, can preferably bind specifically to tumor-specific antigens and / or cancer cell-specific antigens (as defined herein). In some embodiments, the VHHs or fragments thereof bind to tumor-specific antigens and / or cancer cell-specific antigens, with the variable domain in solution. -8 They bind specifically with a dissociation constant (KD) of M or less. In certain embodiments, the VHH or fragments thereof can specifically bind to HER2 with a dissociation constant (KD) of less than 5 nM, for example, from 1 to a maximum of 5 nM, preferably from 2 to a maximum of 3 nM.

[0160] The specific binding of VHH to tumor antigens or cancer cell antigens can be measured by various appropriate methods, including, for example: biopanning, scatchard analysis, and / or competitive binding assays, such as radioimmunoassays (RIAs), enzyme immunoassays (EIAs), and sandwich competitive assays, as well as various modifications thereof known in the art.

[0161] In further specific embodiments, the VHH or fragments thereof used as biological residues in the method for attaching biological residues according to the present invention include at least one combination of CDR sequences selected from the group including: - CDR1 region having sequence number 1, CDR2 region having sequence number 2, and CDR3 region having sequence number 3, and / or - CDR1 region having sequence number 4, CDR2 region having sequence number 5, and CDR3 region having sequence number 6.

[0162] Sequence IDs 7 and 8 give the amino acid sequences of exemplary heavy chain variable domains induced against HER2.

[0163] In some embodiments, the VHH used as a biological residue in the method according to the present invention is directed to a tumor-specific or cancer cell-specific target antigen and has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with at least 60%, at least 65%, at least 70%, at least 70%, at least 75%, at least 85%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. In some embodiments, the VHH or fragments thereof that are directed towards tumor-specific or cancer cell-specific target antigens are encoded by nucleic acids having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the nucleic acid sequence encoding such heavy chain variable domains or fragments thereof.

[0164] In some embodiments, heavy chain variable domain sequences, such as those disclosed herein, can bind to and / or point to HER2, and they have at least 90% amino acid identity with at least one of the heavy chain variable domains of SEQ ID NO: 7 or 8 (wherein amino acid residues forming the CDR sequence are ignored for the purpose of measuring the degree of amino acid identity).

[0165] In some embodiments, the VHH used as a biological residue in the method according to the present invention is directed toward a tumor-specific or cancer cell-specific target antigen, wherein the VHH includes an amino acid sequence selected from SEQ ID NOs: 9-13.

[0166] In some embodiments, the VHH used as a biological residue in the method according to the present invention is directed to a tumor-specific or cancer cell-specific target antigen and has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with at least one of the heavy chain variable domains of SEQ ID NOs. In some embodiments, the VHH or fragments thereof that are directed towards tumor-specific or cancer cell-specific target antigens are encoded by nucleic acids having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the nucleic acid sequence encoding such heavy chain variable domains or fragments thereof.

[0167] In some embodiments, heavy chain variable domain sequences, such as those disclosed herein, can bind to and / or point to HER2, and they have at least 90% amino acid identity with at least one of the heavy chain variable domains of SEQ ID NOs. 9-13 (wherein amino acid residues forming the CDR sequence are ignored for the purpose of measuring the degree of amino acid identity).

[0168] In some embodiments, the radiolabeled VHH domains or fragments thereof used as biological residues in the method for attaching biological residues according to the present invention may optionally be linked to one or more further groups, moieties, or residues via one or more linkers. These one or more further groups, moieties, or residues may help to bind to other targets of interest. It should be clarified whether such further groups, residues, moieties, and / or binding sites can impart or not impart further functionality to the heavy chain variable domains as disclosed herein, and whether or not they can alter the properties of the heavy chain variable domains as disclosed herein. Such groups, residues, moieties, or binding units may further be, for example, chemical groups capable of biological function.

[0169] In some embodiments, these groups, parts, or residues are N-terminally or C-terminally, particularly C-terminally, to the heavy chain variable domain.

[0170] In some embodiments, the VHH domains or fragments thereof used as biological residues in the method for attaching biological residues according to the present invention may be chemically denatured. For example, such denaturation may involve introducing or linking one or more functional groups, residues, or moieties into or on the heavy chain variable domain. These groups, residues, or moieties may confer one or more desired properties or functionalities to the heavy chain variable domain. Examples of such functional groups will be obvious to those skilled in the art.

[0171] For example, introducing or linking such functional groups to a heavy chain variable domain can increase the solubility and / or stability of the heavy chain variable domain, reduce its toxicity, eliminate or reduce various undesirable side effects of the heavy chain variable domain, and / or obtain other advantageous properties.

[0172] In certain embodiments, one or more groups, residues, or moieties are linked to the heavy chain variable domain via one or more suitable linkers or spacers.

[0173] In some embodiments, one or more groups, residues, or parts do not confer an extended half-life to radiolabeled VHH or fragments thereof as disclosed herein. Therefore, in some embodiments, the radiolabeled VHH or fragments thereof used as biological residues in the method for attaching biological residues according to the present invention are not lifetime-extended.

[0174] While the radiolabeled VHH domains specifically bound to tumor-specific antigens and / or cancer cell-specific antigens used as biological residues in the method for attaching biological residues in the present invention are generally in monomeric form, in certain alternative embodiments, two or more radiolabeled VHHs or their fragments as described above may be linked together or interlinked. In certain embodiments, two or more VHHs or their fragments are linked together via one or more suitable linkers or spacers. Suitable spacers or linkers for coupling different VHHs will be obvious to those skilled in the art and may be any linkers or spacers commonly used in the art to link peptides and / or proteins.

[0175] Some exemplary suitable linkers or spacers include, but are not limited to, polypeptide linkers such as glycine linkers, serine linkers, mixed glycine / serine linkers, glycine-rich and serine-rich linkers, or linkers composed of mostly polar polypeptide fragments, or homo- or hetero-bifunctional chemical crosslinking compounds such as glutaraldehyde, or possibly maleimide or NHS esters spaced by PEG.

[0176] Methods for carrying out chemical reactions As described above, the reaction in the present invention is a post-labeling reaction of a radioactive compound. By definition, the chemical reaction does not result in the formation of new bonds on the radionuclides contained in the radioactive compound. Nevertheless, the reaction in the present invention may consist of a broader chemical reaction in which the radioactive compound is formed as an intermediate, and in which the broader reaction includes a reaction in which new bonds are formed on the radionuclides.

[0177] Therefore, in a second embodiment, the present invention provides a method for obtaining a radioactive reaction product, wherein the method includes the following steps: (i) A step of producing a radioactive compound in the form of a mixture; thereafter, (ii) The step of carrying out a post-labeling chemical reaction of the radioactive compound comprising the mixture, wherein the post-labeling chemical reaction is carried out using a method according to the present invention, wherein the radioactive reaction product is the reaction product of the post-labeling chemical reaction.

[0178] In the context of this second aspect of the present invention, unless otherwise specified, the same definitions and descriptions as defined above in the context of the first aspect of the present invention apply. Furthermore, all preferred embodiments and features of the method according to the present invention, as disclosed above, also apply to step (ii) of the method according to this second aspect, with modifications as necessary.

[0179] In one preferred embodiment, a method according to this second aspect is provided, wherein step (i) carries out a chemical reaction between a precursor and a radioactive component, wherein the precursor does not contain a radionuclide.

[0180] Preferably, the precursor is an organic compound, more preferably, the precursor is N-succinimidyl-4-[1,2-bis(tert-butyloxycarbonyl)guanidinomethyl]-3-(trimethyl-stannyl)benzoate (Boc2-SGMTB) or N-succinimidyl-3-[1,2-bis(tert-butyloxycarbonyl)guanidinomethyl]-5-(trimethyl-stannyl)benzoate (iso-Boc2-SGMTB), and most preferably, the precursor is N-succinimidyl-4-[1,2-bis(tert-butyloxycarbonyl)guanidinomethyl]-3-(trimethyl-stannyl)benzoate (Boc2-SGMTB).

[0181] The radioactive component is preferably an inorganic compound containing a radionuclide, more preferably an inorganic salt or a binary acid of a radionuclide, and even more preferably a sodium salt or binary acid, and most preferably the radioactive component is Na 131 It is I.

[0182] In one preferred embodiment, a method according to this second aspect is provided, wherein the method is automated.

[0183] Heating device In a third embodiment, the present invention provides a device (1) for housing and heating a chemical reaction vessel (3) containing a mixture, wherein the device (1) includes a heating means (5) and an opening (2) configured to house the chemical reaction vessel (3), the heating means (5) at least partially enclosing the opening; wherein the heating means includes: - Polymers for thermal insulation (9), - A resistive conductor (8) embedded in the aforementioned polymer for thermal insulation; Here, the device (1) is configured to heat the mixture present in the chemical reaction vessel (3) according to predetermined temperature requirements by applying an electric current to the heating means (5) when the chemical reaction vessel (3) containing the mixture is present in the opening (2); preferably, here, the device (1) is a cylindrical sleeve, and the opening is a lumen surrounded by the device (1). A device according to this third aspect of the present invention is referred to in this application as the device of the present invention.

[0184] The method according to the present invention preferably involves the use of the device according to the present invention or is carried out on said device. Herein, the mixture described in the context of the device according to the present invention is the mixture containing a radioactive compound as described in the context of the method according to the present invention, wherein the radioactive compound does not contain fluorine-18, and the heating of the mixture is at a temperature selected in the range of 30°C to a maximum of 150°C; and the step (b) of heating the mixture in the method is achieved by the energization of the heating means contained within the device. The chemical reaction is preferably carried out in the chemical reaction vessel as defined in the context of the method according to the present invention. In this view, all embodiments and preferred embodiments disclosed in the context of the method according to the present invention can be applied to the device according to the present invention with modifications as necessary.

[0185] The device in this invention provides surface heating, which is advantageous in that it is non-intrusive while allowing for optimal control of the heating process. This effectively eliminates the need to worry about delicate materials or critical maximum temperatures. This avoids problems associated with hot spots and localized overheating. In addition, because it is non-intrusive, the practicality of introducing and cleaning intrusive heating devices is avoided. Furthermore, because surface heating using polymer insulation, and especially embodiments using flexible silicone, results in a lightweight and compact device that can be fabricated only for a specific chemical reaction vessel and / or a specific chemical reaction. In addition, surface heating using polymer insulation provides low thermal mass, advantageous electrical insulation performance, and a robust structure, enabling high power density and a fast response to temperature control. Moreover, the heating device in this invention is simple, making it easy to ensure compliance with predetermined temperature requirements.

[0186] In a fourth embodiment, the present invention provides a system (10) for carrying out a chemical reaction in a mixture, which includes: - Device according to the present invention (1); - A chemical reaction vessel (3) placed in the opening (2) of the device (1), wherein the chemical reaction vessel (3) includes a reactor chamber (30), an inlet (31), a housing, and preferably a solid phase suitable for functioning as a facilitator of the chemical reaction, Here, the system (10) is configured such that, once the mixture is introduced into the reactor chamber (30) through the inlet (31), the heating means (5) is energized to heat the mixture present in the chemical reaction vessel (3) according to predetermined temperature requirements, thereby causing the chemical reaction to occur in the reaction chamber (30). A system according to this fourth aspect of the present invention is referred to in this application as the system of the present invention.

[0187] As is obvious to those skilled in this field, the main difference between the device in the present invention and the system in the present invention is whether or not a chemical reaction vessel is included. Therefore, the device in the present invention can be imagined as the system in the present invention, but without the chemical reaction vessel placed inside the opening of the device.

[0188] Preferably, the method according to the present invention includes the use of the system according to the present invention. Here, the mixture described in the context of the system according to the present invention is the mixture containing a radioactive compound as described in the context of the method according to the present invention, wherein the radioactive compound does not contain fluorine-18; and the heating of the mixture is to a temperature selected in the range of 30°C to a maximum of 150°C; the solid phase contained in the chemical reaction vessel is the solid phase in step (a) of the method according to the present invention; and (b) the heating of the mixture in the method is achieved by the electrocharging of the heating means contained in the device or system. In other words, in this preferred embodiment, the chemical reaction is the chemical reaction according to the present invention. In this view, all embodiments and preferred embodiments disclosed in the context of the method according to the present invention can be applied to the system according to the present invention with modifications as necessary.

[0189] In a fifth embodiment, the present invention provides a method for carrying out a chemical reaction in a mixture, the method comprising the following steps: - A step comprising a system for carrying out a chemical reaction in a mixture, wherein the system includes the following: A device (1) for housing and heating a chemical reaction vessel (3) containing a mixture [the device (1) includes a heating means (5) and an opening (2) configured to house the reaction vessel (3), wherein the heating means (5) at least partially surrounds the opening]; A chemical reaction vessel (3) is placed inside the opening (2) [the chemical reaction vessel (3) includes a reactor chamber (30), an inlet (31), a housing (33), and a solid phase (preferably suitable for functioning as a facilitator in the chemical reaction)]; - A step of introducing the mixture into the reactor chamber (3) through the inlet (31); - A step of heating the mixture present in the chemical reaction vessel (3) according to predetermined temperature requirements by applying electric current to the heating means (5), thereby causing the chemical reaction to occur inside the reaction chamber (30).

[0190] In accordance with the embodiments described above, the system for carrying out a chemical reaction in a mixture is preferably the system of the present invention. In the context of this application, a method according to this preferred definition is referred to as a method carried out using the system of the present invention. More preferably, a method carried out using the system of the present invention is the method according to the present invention. In other words, the system of the present invention is more preferably used to carry out a chemical reaction according to the present invention.

[0191] The embodiments and preferred embodiments described below relate to the devices, systems, and / or methods carried out using the systems of the present invention.

[0192] In the context of the present invention, predetermined temperature requirements are preferably related to various combinations of parameters that define the thermal conditions of the chemical reaction vessel and its contents. Specifically, these predetermined temperature requirements may include: a maximum temperature, and / or a time window during which the temperature between the minimum and maximum temperatures is maintained, and / or a maximum time for heating, and / or a minimum or maximum time for the chemical reaction to occur.

[0193] In an exemplary embodiment, the predetermined temperature requirement is preferably, for example, starting from an initial temperature of 30°C, 40°C, 50°C, 60°C, or 70°C, the temperature is increased over various time intervals between 5 seconds and 1 hour, for example, 3 minutes, from 30°C to a maximum of 250°C, from 30°C to a maximum of 250°C, from 30°C to a maximum of 240°C, from 30°C to a maximum of 230°C, from 30°C to a maximum of 220°C, from 30°C to a maximum of 210°C, from 30°C to a maximum of 200°C, from 30°C to a maximum of 190°C, and from 30°C to a maximum of 18 The requirement may relate to a target temperature for the mixture in various temperature ranges, including up to 0°C, 30°C to a maximum of 170°C, 30°C to a maximum of 160°C, 30°C to a maximum of 150°C, 30°C to a maximum of 140°C, 30°C to a maximum of 130°C, 30°C to a maximum of 120°C, 30°C to a maximum of 110°C, 30°C to a maximum of 100°C, 30°C to a maximum of 90°C, 30°C to a maximum of 80°C, 30°C to a maximum of 70°C, 30°C to a maximum of 60°C, and 30°C to a maximum of 50°C. The predetermined temperature requirement may further specify one or more parameters relating to the transition from the initial temperature to the target temperature, such as the maximum time required for the transition and / or the amount of over-transition being less than 5°C, preferably less than 1°C.

[0194] Preferably, the target temperature of the mixture is selected from the following ranges: 30°C to a maximum of 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, or 150°C. Preferably, the target temperature of the mixture is selected from the following ranges: 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, or 65°C to a maximum of 70°C. Preferably, the target temperature of the mixture is selected from the following ranges: 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, or 145°C, up to a maximum of 150°C.

[0195] Preferably, the target temperature of the mixture is selected from the following ranges: 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, or 145°C, each within a range of ±10°C. Preferably, the target temperature of the mixture is selected from the following ranges: 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, or 140°C, each within a range of ±20°C. Preferably, the target temperature of the mixture is selected from the following ranges: 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, or 135°C, each within a range of ±30°C. Preferably, the target temperature of the mixture is selected from the following ranges: 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, or 130°C, each within a range of ±40°C. Preferably, the target temperature of the mixture is selected from the following ranges: 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, or 125°C, each within a range of ±50°C.

[0196] Preferably, the predetermined temperature requirement means that the mixture is required to reach a target temperature selected from 30°C to a maximum of 70°C at a time selected from 1 minute to a maximum of 15 minutes, or a target temperature selected from 30°C to a maximum of 55°C at a time selected from 1 minute to a maximum of 15 minutes, or a target temperature selected from 30°C to a maximum of 70°C at a time selected from 1 minute to a maximum of 10 minutes, or a target temperature selected from 30°C to a maximum of 55°C at a time selected from 1 minute to a maximum of 5 minutes, or a target temperature selected from 30°C to a maximum of 55°C at a time selected from 1 minute to a maximum of 5 minutes.

[0197] The devices of the present invention may use chemical reaction vessels of various commonly used dimensions, but the embodiments disclosed herein include all embodiments of devices having dimensions suitable for use in an SPE cartridge, as known to those skilled in the art. In embodiments in which the device includes a metal sleeve, the metal sleeve may facilitate the adaptation of the device to chemical reaction vessels having different maximum dimensions of cross-sectional area, for example, different cylindrical chemical reaction vessels having different diameters. Examples of dimensions for the metal sleeve are given below: length from 10 mm to a maximum of 100 mm, e.g., 25 mm, and / or inner diameter from 2 mm to a maximum of 30 mm, e.g., 11 mm, and / or outer diameter from 3 mm to a maximum of 35 mm, e.g., 15.9 mm or 16 mm. In embodiments, the length and / or resistance value and / or maximum output of the resistive conductor are adapted as a function of the dimensions and / or requirements of the chemical reaction vessel selected for use in the device and / or predetermined temperature requirements.

[0198] In the embodiment, the maximum output (also called the power rating) of the resistive conductor is 150W, 140W, 130W, 120W, 110W, 100W, 90W, 80W, 70W, 60W, 50W, 40W, 30W, 20W, 10W, or 5W.

[0199] In embodiments, the insulating polymer of the heating means or heating pad includes silicone or silicone rubber. An advantage of such a material is that it provides a device and heating pad that can be rugged, water-resistant and / or chemical-resistant. Furthermore, such a heating pad can be easily connected to other parts of the device for effective heat transfer. Silicone rubber is advantageous in that it can withstand extremely high temperatures without degradation. Furthermore, the sealing of the silicone rubber allows for a sufficiently waterproof connection. In embodiments, the insulating polymer containing silicone, and / or the device containing the insulating polymer containing silicone, is suitable for temperatures above 50°C, preferably above 100°C, more preferably above 200°C, and most preferably above 250°C. In preferred embodiments, the insulating polymer containing silicone, and / or the device containing the insulating polymer containing silicone, is suitable for temperatures from 50°C, or from 100°C, or from 200°C, up to 300°C. In a preferred embodiment, the melting temperature of the polymer for thermal insulation is higher than 150°C, and preferably higher than 200°C.

[0200] In the embodiment, the insulating polymer of the heating means includes polyimide. The advantage of such a material is that it is a thin, lightweight, transparent material, giving a thin, lightweight device. In the embodiment, the insulating polymer containing polyimide and / or the device containing the insulating polymer containing polyimide are suitable for the following temperatures: - Over 50°C, preferably over 100°C, more preferably over 150°C, most preferably over 200°C, and / or - Less than 400°C, preferably less than 350°C, more preferably less than 300°C, and / or - Within the range of 50°C to 400°C, preferably within the range of 50°C to 350°C, more preferably within the range of 50°C to 300°C.

[0201] In embodiments, the heating means includes a wound element embedded or, synonymously, embedded within a polymer insulation material. Advantages of such a wound element include physical strength and flexibility, where repeated bending of the heater does not negatively affect its performance. Another advantage relates to its ability to easily conform to curved surfaces, including small-radius bends, enabling slim and / or small-diameter devices. Yet another advantage is that the heater can be repeatedly bent during installation and removal without internal damage, thus facilitating production.

[0202] In the embodiment, the resistive conductor of the heating means has an insulation resistance greater than 100 kΩ, preferably greater than 1 MΩ, and preferably at least 10 MΩ.

[0203] In embodiments, the heating means includes etched foil elements embedded or, synonymously, embedded within a polymer insulation material. Advantages of such etched foil elements include good circuit pattern reproducibility and excellent heat transfer, thereby expanding the range of applications for the element. Other advantages relate to the delivery of increased heat and / or increased watt density and / or increased heater life. Yet another advantage relates to the ability to create complex heat distribution patterns and / or multiple zoning patterns.

[0204] In this embodiment, the heating means is a flexible sheet, - Here, preferably, the flexible sheet has a rectangular shape; and / or - Here, preferably, the thickness of the flexible sheet is from 0.5 mm to a maximum of 1.5 mm, more preferably from 0.5 mm to a maximum of 1.0 mm.

[0205] In this embodiment, the heating means is a flexible sheet, wherein the flexible sheet has a rectangular shape, and the rectangular shape has a width of 20 mm to a maximum of 200 mm and a length of 20 mm to a maximum of 200 mm, or a width of 20 mm to a maximum of 150 mm and a length of 20 mm to a maximum of 150 mm, or a width of 20 mm to a maximum of 100 mm and a length of 20 mm to a maximum of 100 mm, preferably the thickness of the flexible sheet is 0.5 mm to a maximum of 1.5 mm, more preferably 0.5 mm to a maximum of 1.0 mm.

[0206] In this embodiment, the heating means is a flexible sheet, wherein the flexible sheet has a rectangular shape, and here: - The rectangular shape has a width of 20 mm to a maximum of 30 mm and a length of 45 mm to a maximum of 55 mm, preferably a width of 25 mm and a length of 50 mm, where the maximum output of the resistive conductor is 5 W; or, - The rectangular shape has a width of 45 mm to a maximum of 55 mm and a length of 45 mm to a maximum of 55 mm, preferably a width of 50 mm and a length of 50 mm, preferably such that the maximum output of the resistive conductor is 10 W; or, - The rectangular shape has a width of 45 mm to a maximum of 55 mm and a length of 70 mm to a maximum of 80 mm, preferably a width of 50 mm and a length of 75 mm, preferably such that the maximum output of its resistive conductor is 15 W; or, - The rectangular shape has a width of 45 mm to a maximum of 55 mm and a length of 95 mm to a maximum of 105 mm, preferably a width of 50 mm and a length of 100 mm, preferably such that the maximum output of its resistive conductor is 20 W; or, - The rectangular shape has a width of 45 mm to a maximum of 55 mm and a length of 145 mm to a maximum of 155 mm, preferably a width of 50 mm and a length of 150 mm, wherein the maximum output of the resistive conductor is 30 W; or, - The rectangular shape has a width of 70 mm to a maximum of 80 mm and a length of 95 mm to a maximum of 1052 mm, preferably a width of 75 mm and a length of 100 mm, preferably such that the maximum output of its resistive conductor is 30 W; or, - The rectangular shape has a width of 95 mm to a maximum of 105 mm and a length of 95 mm to a maximum of 105 mm, preferably a width of 100 mm and a length of 100 mm, where preferably the maximum output of the resistive conductor is 40 W; or, - The rectangular shape has a width of 95 mm to a maximum of 105 mm and a length of 145 mm to a maximum of 155 mm, preferably a width of 100 mm and a length of 150 mm, where preferably the maximum output of the resistive conductor is 60 W; or, - The rectangular shape has a width of 70 mm to a maximum of 80 mm and a length of 195 mm to a maximum of 205 mm, preferably a width of 75 mm and a length of 200 mm, preferably such that the maximum output of its resistive conductor is 60 W; or, - The rectangular shape has a width of 145 mm to a maximum of 155 mm and a length of 195 mm to a maximum of 205 mm, preferably a width of 150 mm and a length of 200 mm, preferably where the maximum output of the resistive conductor is 120 W; Preferably, the thickness of the flexible sheet is between 0.5 mm and a maximum of 1.5 mm.

[0207] In the embodiment, the flexible sheet includes a reinforcing layer covering one side of the flexible sheet, preferably, the reinforcing layer being made of glass and / or glass fibers. This has the advantage of providing high structural integrity.

[0208] In embodiments, the device of the present invention includes a metal sleeve placed between a chemical reaction vessel and a heating means and surrounding the chemical reaction vessel, wherein the metal is preferably copper. In embodiments, the metal sleeve may be related to a plurality of interchangeable or replaceable metal sleeves taken from a plurality of metal sleeves, wherein the plurality is characterized by at least two different thicknesses and / or at least two different inner or outer diameters. The presence of the metal sleeve facilitates the adaptation of the device to chemical reaction vessels having different maximum dimensions of cross-sectional area, for example, different cylindrical chemical reaction vessels having different diameters.

[0209] In embodiments, the device of the present invention includes a metal sleeve placed between a chemical reaction vessel and a heating means and surrounding the chemical reaction vessel, wherein the metal is preferably copper, and the mass of the metal sleeve is from 10 g to a maximum of 550 g, preferably from 20 g to a maximum of 550 g.

[0210] In embodiments, the device of the present invention includes a metal sleeve placed between a chemical reaction vessel and a heating means and surrounding the chemical reaction vessel, wherein the metal is preferably copper, and the ratio between the maximum output of the resistive conductor and the mass of the metal sleeve is 0.5 W / g, 0.45 W / g, 0.4 W / g, 0.35 W / g, 0.3 W / g, 0.25 W / g, 0.2 W / g, 0.15 W / g, or 0.1 W / g.

[0211] In embodiments, the device of the present invention includes a metal sleeve placed between a chemical reaction vessel and a heating means and surrounding the chemical reaction vessel, wherein the metal is preferably copper, the mass of the metal sleeve is from 10 g to a maximum of 550 g, and the ratio between the maximum output of the resistive conductor and the mass of the metal sleeve is 0.5 W / g, 0.45 W / g, 0.4 W / g, 0.35 W / g, 0.3 W / g, 0.25 W / g, 0.2 W / g, 0.15 W / g, or 0.1 W / g.

[0212] In embodiments, the device of the present invention further includes a cover, which conveniently keeps the device as a whole. The cover may include, for example, one or more holes for supplying power to the heating means, which can reduce the risk of tearing and provide greater robustness to the electrical connections of the heating means.

[0213] In embodiments, the heating means preferably includes an adhesive layer for attaching the heating means to the metal sleeve or a cover surrounding the heating means, in order to attach the heating means to a further part of the device in the present invention. This has advantages such as easier installation of the device and / or improved structural integrity of the device and / or improved thermal conductivity for heat transfer from the heating means to the metal sleeve.

[0214] In embodiments, the device of the present invention includes a control unit, which controls the power supplied to the heating means to set the predetermined temperature requirements related to the temperature of the mixture to 30°C to a maximum of 250°C, 30°C to a maximum of 250°C, 30°C to a maximum of 240°C, 30°C to a maximum of 230°C, 30°C to a maximum of 220°C, 30°C to a maximum of 210°C, 30°C to a maximum of 200°C, 30°C to a maximum of 190°C, and 30°C to a maximum of 1 The system is configured to maintain the temperature within a predetermined sub-range, which includes the ranges of up to 80°C, 30°C to a maximum of 170°C, 30°C to a maximum of 160°C, 30°C to a maximum of 150°C, 30°C to a maximum of 140°C, 30°C to a maximum of 130°C, 30°C to a maximum of 120°C, 30°C to a maximum of 110°C, 30°C to a maximum of 100°C, 30°C to a maximum of 90°C, 30°C to a maximum of 80°C, 30°C to a maximum of 70°C, 30°C to a maximum of 60°C, and 30°C to a maximum of 50°C. The control unit is characterized by controlling the current of electrical energy from the power source to the heating means. In embodiments, the control unit includes a relay, providing a simple and reliable means of controlling the heat supply. In embodiments, the control unit consists of a programmable logical controller, which is preferably connected to the heating means via insulated leads, preferably PTFE-insulated leads. In embodiments, the device further includes a temperature sensor, and the control is based on measurements by the temperature sensor. This offers the advantage of improved control over the heat supplied to the chemical reaction vessel. This can relate to more accurate and / or faster adaptation to predetermined temperature requirements, for example, by preventing overheating and / or reaching a stable temperature after a rapid and short equilibrium time.In the embodiment, a temperature sensor, which may consist of one or more sensor elements, is positioned in part of the heating means, and / or between the heating means and the metal sleeve (if present), and / or between the heating means and the chemical reaction vessel, and / or at a further location in the chemical reaction vessel (for example, on the inlet or outlet side).

[0215] In the embodiment, the predetermined temperature requirements are met by means of a control unit, which is a programmable logical controller (PLC). Preferably, the temperature is measured by means of a temperature sensor, including a thermocouple board of the PLC. Preferably, the control unit is configured so that the temperature is controlled according to PID control. This relates to specific parameters configured to avoid overheating.

[0216] In the embodiment, the device of the present invention is a cylindrical sleeve, and the opening is a lumen surrounded by the device.

[0217] In embodiments, the chemical reaction vessel included in the system of the present invention further includes an outlet (32). In embodiments, the chemical reaction vessel is an SPE cartridge.

[0218] In the embodiments, the chemical reaction vessel incorporated into the system of the present invention has the following heights: 5 mm to a maximum of 500 mm, or 5 mm to a maximum of 450 mm, or 5 mm to a maximum of 400 mm, or 5 mm to a maximum of 350 mm, or 5 mm to a maximum of 300 mm, or 5 mm to a maximum of 250 mm, or 5 mm to a maximum of 200 mm, or 5 mm to a maximum of 150 mm, or 5 mm to a maximum of 100 mm.

[0219] In embodiments, the chemical reaction vessel incorporated into the system of the present invention has the following diameters: 1 mm to a maximum of 200 mm, or 1 mm to a maximum of 190 mm, or 1 mm to a maximum of 180 mm, or 1 mm to a maximum of 170 mm, or 1 mm to a maximum of 160 mm, or 1 mm to a maximum of 150 mm, or 1 mm to a maximum of 140 mm, or 1 mm to a maximum of 130 mm, or 1 mm to a maximum of 120 mm, or 1 mm to a maximum of 110 mm, or 1 mm to a maximum of 100 mm, or 1 mm to a maximum of 90 mm, or 1 mm to a maximum of 80 mm, or 1 mm to a maximum of 70 mm, or 1 mm to a maximum of 60 mm, or 1 mm to a maximum of 50 mm.

[0220] In embodiments, the chemical reaction vessel incorporated into the system of the present invention has a diameter of 11 mm to a maximum of 12 mm and a height of 10.5 mm to a maximum of 11.5 mm. Preferably, the diameter is 11.5 mm and the height is 11 mm.

[0221] In embodiments, the chemical reaction vessel incorporated into the system of the present invention has a diameter of 11 mm to a maximum of 12 mm and a height of 19.5 mm to a maximum of 20.5 mm. Preferably, the diameter is 11.5 mm and the height is 20 mm.

[0222] In the embodiments, the volume enclosed by the chemical reaction vessel incorporated into the system of the present invention is 100 μm to 1 mL, preferably 200 μL to a maximum of 800 μL, and more preferably 300 μL to a maximum of 700 μL.

[0223] In embodiments, the housing of a chemical reaction vessel incorporated into the system of the present invention is made of metal and / or a metal alloy and / or glass and / or glass fiber and / or an organic polymer. In embodiments, the housing is made of one or more organic polymers.

[0224] In embodiments, the solid phase contained in the chemical reaction vessel of the system of the present invention is silica, and preferably the solid phase comprises one or more of Sep-Pak tC18, Step-Pak C18, Oasis HLB, Oasis MCX, Oasis MAX, and Sephadex LH-20, and preferably the solid phase is Sep-Pak tC18.

[0225] In embodiments, the mass of the solid phase contained in the chemical reaction vessel of the system according to the present invention ranges from 1 mg to a maximum of 1 g.

[0226] definition Each embodiment presented herein may be combined with others unless otherwise specified. All patents and documents referenced herein are incorporated herein by reference.

[0227] In this specification and in the patent claims, the verb “comprise” and its conjugations are used in their non-restrictive sense, meaning that the items following the word are included, but items not specifically mentioned are excluded. In addition, the verb “consist” may be replaced with the expression “consist essentially of,” meaning that the methods defined herein may include additional steps or components beyond those specifically mentioned, and such additional components do not alter the unique characteristics of the invention. Furthermore, references to elements using the indefinite article “a” or “an” do not exclude the possibility of two or more elements being present, unless the context explicitly claims that there is one and only one element. Thus, the indefinite article “a” or “an” usually means “at least one.”

[0228] In the context of the present invention, an increase or decrease in the parameter being evaluated means a change of at least 5% in the value corresponding to that parameter. More preferably, an increase or decrease in a numerical value means a change of at least 10%, even more preferably at least 20%, at least 30%, at least 40%, at least 50%, at least 70%, at least 90%, or 100%. In the latter case, there may be no longer any detectable numerical value in relation to that parameter.

[0229] When a series of numbers are given, such as "at least X, Y, or Z" and "less than X%, Y%, or Z%, such statements should be interpreted as "at least X, or at least Y, or at least Z" and "less than X%, or less than Y%, or less than Z%, respectively."

[0230] To use a substance as described herein as a pharmaceutical product can also be interpreted as using such substance in the production of a pharmaceutical product. Similarly, if a substance is used for therapeutic purposes or as a pharmaceutical product, it may be used in the production of a pharmaceutical product for therapeutic purposes.

[0231] In relation to a numerical value, the terms "about" or "approximately" (for example, about 10) preferably mean that the numerical value may be a value within plus or minus 0.1% of the given numerical value (in this case, 10).

[0232] In relation to integers, the expression "between" refers to a range that includes the specified boundary value. For example, if n is a number between 1 and 3, then n can be 1, 2, or 3. In other words, "between X and Y" is synonymous with "from X up to a maximum of Y".

[0233] In the context of this invention, "represented by structure X," "of structure X," and "with structure X" are interchangeable.

[0234] The term "affinity," as used herein, refers to the degree to which a polypeptide, particularly an immunoglobulin such as an antibody, or an immunoglobulin fragment such as VHH, binds to an antigen and shifts the equilibrium between the antigen and the polypeptide toward the presence of the complex formed by their binding. Therefore, for example, if an antigen and an antibody (e.g., an antibody fragment) are bound at relatively equal concentrations, a high-affinity antibody (e.g., an antibody fragment) will bind to the available antigen and shift the equilibrium toward a higher concentration of the resulting complex. The dissociation constant (KD) is commonly used to describe the affinity between a protein-binding domain and an antigen target. Typically, the dissociation constant is 10⁻¹⁰. -5 It is less than M. In some embodiments, the dissociation constant between the antigen and the biological residue used in the method for attaching the biological residue in the present invention is 10 -6 Less than M, more preferably 10 -7 Less than M, most preferably 10 -8 Less than M, for example 10 -9 It is less than M.

[0235] The terms "specifically bind" and "specific binding," as used herein, generally refer to the ability of a polypeptide, particularly an immunoglobulin such as an antibody, or a fragment of an immunoglobulin such as VHH, or such fragment, which can be used as a biological residue in the method for attaching biological residues in the present invention, to preferentially bind to a specific antigen present in a homogeneous mixture of different antigens. In certain embodiments, the specific binding interaction will distinguish between desired and undesirable antigens in a sample by a factor of about 10 to 100 or more (e.g., about 1,000 or more than 10,000) in some embodiments.

[0236] Therefore, an amino acid sequence, particularly an antibody fragment, such as a VHH or fragment thereof disclosed herein as a biological residue used in a method for attaching biological residues in the present invention, is said to "specifically bind" to a particular target if the amino acid sequence has affinity, specificity, and / or specifically directs to its target (or at least a portion of such fragment).

[0237] The "specificity" of an amino acid sequence, particularly an antibody fragment, such as VHH, or such fragment, that can be used as a biological residue in the method for attaching biological residues according to the present invention, can be determined based on affinity and / or avidity. The "affinity" of an amino acid sequence contained in the biological residue used in the method for attaching biological residues according to the present invention is expressed by the equilibrium constant for the dissociation of the amino acid sequence, which may be the biological residue used in the method for attaching biological residues according to the present invention, and may also be the target protein of interest to which it is bound. A lower KD value indicates a stronger binding strength between the amino acid sequence contained in the biological residue used in the method for attaching biological residues according to the present invention, and the target protein of interest to which it is bound. Alternatively, affinity can also be expressed by an affinity constant (KA), which corresponds to 1 / KD. The binding affinity of an amino acid sequence that may be contained in the biological residue used in the method for attaching biological residues according to the present invention can be determined by methods known to the art, depending on the specific target protein of interest. The “binding activity” of an amino acid sequence that may be included in the biological residues used in the method for attaching biological residues according to the present invention is a measure of the binding strength between the amino acid sequence and the relevant target protein of interest. Binding activity is related to both the affinity between the binding site on the target protein of interest and the binding site on the amino acid sequence, and the number of relevant binding sites present on that amino acid sequence. In some embodiments, the amino acid sequence included in the biological residues used in the method for attaching biological residues according to the present invention will bind to the target protein of interest having a dissociation constant (KD) of less than about 1 micromolar (1 μM), preferably less than about 1 nanomolar (1 nM) [i.e., an association constant (KA) of about 1,000,000 / mol (10⁻¹⁰ 6 M -1 , 1E6 / M) or more, preferably about 1,000,000,000 / mol (109 M -1 [1E9 / M) or higher]. A KD value higher than approximately 1 millimolar is generally considered to indicate non-binding or non-specific binding. As is generally known in this industry, KD is the dissociation rate constant of the complex [k0ff (unit, seconds). -1 or s -1 The rate constant of the association [k0n (unit, moles)] is expressed as follows: -1 seconds -1 Or M -1 s -1 It can also be expressed as a ratio to [represented by )]. In some embodiments, the amino acid sequence contained in the biological residue used in the method for attaching biological residues in the present invention is 0.1 to 0.0001s -1 koff in the range between and / or 1,000~1,000,000M -1 s -1 It will bind to the target protein of interest having k0n in the range between . The binding affinity, k0ff, and k0n ratio can be determined by means or methods known to those skilled in the art, such as ELISA, isothermal titration calorimetry, surface plasmon resonance, fluorescence-activated cell sort analysis, etc.

[0238] With respect to amino acid sequences, particularly antibody fragments, such as VHH or fragments thereof, that can be used as biological residues in the methods for attaching biological residues according to the present invention, the terms “binding region,” “binding site,” or “interaction site” located on an amino acid sequence that may be included in the biological residues used in the methods for attaching biological residues according to the present invention should, as herein, mean a specific site, portion, domain, or stretch of amino acid residues within that amino acid sequence that is responsible for binding to the target molecule. In some embodiments, such a binding region consists substantially of specific amino acid residues from an amino acid sequence that is in contact with the target molecule.

[0239] In the method for attaching biological residues according to the present invention, an amino acid sequence, particularly an antibody fragment, such as VHH, or all of two or more binding sites of such fragments, is said to be “divalent” (in the case of two binding sites on the amino acid sequence) or polyvalent (in the case of three or more binding sites on the amino acid sequence), for example, trivalent, if such amino acid sequence may be a biological residue used in the method for attaching biological residues according to the present invention, and all of these binding sites point to or specifically bind to the same site, determinant, part, domain, or stretch of an amino acid residue of interest.

[0240] As used herein, the term “monovalent” in relation to antibody fragments, e.g., VHHs, or such fragments, refers to antibody fragments in monomeric form. A monovalent antibody fragment contains only one binding site. In this context, the binding site of an antibody fragment, e.g., a VHH, or such fragments, contains one or more “complementarity-determining regions” or “CDRs” of the antibody fragment that are directed to or specifically bind to a particular site, determinant, part, domain, or stretch of amino acid residues of the target of interest.

[0241] As used herein, the term “untagged” means an antibody fragment, such as VHH, or, in relation to such fragments, an antibody fragment that does not contain an exogenous polypeptide sequence. Examples of exogenous polypeptide sequences include: carboxy-terminal polypeptide tags, such as His-tags, cysteine-containing tags (such as GGC-tags), and / or Myc-tags.

[0242] The term “bi-specific” refers to an amino acid sequence, particularly an antibody fragment, e.g., VHH, which may be a biological residue used in the method for attaching biological residues in the present invention, and means either: a) two or more binding sites of an amino acid sequence direct to or specifically bind to the same target of interest, but do not bind to the same site, determinant, part, domain, or stretch of the amino acid residue of that target (i.e., they bind to different ones) [the amino acid sequence is called “bi-specific” (in the case of two binding sites on the amino acid sequence) or “multi-specific” (in the case of three or more binding sites on the amino acid sequence)]; or b) two or more binding sites of an amino acid sequence direct to or specifically bind to different target molecules of interest. The term “multi-specific” is used when there are three or more binding sites on the amino acid sequence.

[0243] In some embodiments, a “bispecific” amino acid sequence or antibody fragment, e.g., “bispecific” VHH, or a “multispecific” amino acid sequence or antibody fragment, e.g., “multispecific” VHH, which may be used in the method for attaching biological residues according to the present invention, should mean an amino acid sequence, particularly an antibody fragment, e.g., VHH, which may be used in the method for attaching biological residues according to the present invention, comprising two or more binding sites, wherein the two or more binding sites have different binding specificities. In some embodiments, an amino acid sequence, particularly an antibody fragment, e.g., VHH, which may be used in the method for attaching biological residues according to the present invention, is considered “bispecific” or “multispecific” if two or more different binding regions are present within the same monomeric amino acid sequence.

[0244] The "half-life" of an amino acid sequence, particularly an antibody fragment, such as VHH or similar fragments, which may be a biological residue used in the method for attaching biological residues in the present invention, can generally be defined as the time required for the in vivo serum concentration of the amino acid sequence to be reduced to 50%. The in vivo half-life of an amino acid sequence can be determined by various methods known to those skilled in the art, such as pharmacokinetic analysis. As will be apparent to those skilled in the art, the half-life can be expressed using parameters such as tl / 2-alpha, tl / 2-beta, and area under the curve (AUC). An increase in the in vivo half-life is generally characterized by an increase in one or more, preferably all three, of the parameters tl / 2-alpha, tl / 2-beta, and area under the curve (AUC).

[0245] The term "lifetime extended" is used to mean that an antibody fragment, such as VHH, or, in the case of such fragments, that has been denatured to extend its half-life, which may be a biological residue used in the method for attaching biological residues in the present invention. Strategies for extending the half-life of antibodies and antibody fragments are well known in the art and include, but are not limited to, attaching one or more groups or parts that extend the half-life (chemically or otherwise), such as polyethylene glycol (PEG), bovine serum albumin (BSA), human serum albumin (HSA), antibody Fc fragments, or antigen-binding antibody fragments targeting serum proteins such as serum albumin.

[0246] A range centered on a predetermined value and having a predetermined width before and after it is a closed interval from the predetermined value minus half of the width to the maximum of the predetermined value plus half of the width. For example, if the temperature is selected within a range of 10°C before and after 35°C, then the temperature range is from 35°C (35°C - 10°C / 2) to a maximum of 40°C (35°C + 10°C / 2). [Brief explanation of the drawing]

[0247] [Figure 1] This is an overview of the synthesis of 131I-SGMIB. [Figure 2] This is a schematic diagram of the deprotection procedure of the tC18 Sep-Pak cartridge. [Figure 3] This is a graph showing the change in the yield of the fully deprotected reaction product as a function of the heating temperature (where the heating is for 20 minutes). [Figure 4] This is a graph showing the change in the yield of the fully deprotected reaction product as a function of the heating temperature (where the heating is for 5 minutes). [Figure 5] This is an example of a cassette used to automate the thermal deprotection of Boc2-protected [*I]I-SGMIB. [Figure 6] These are various diagrams of exemplary embodiments of the devices and systems in the present invention. Figure 1a shows a first broken-away view. Figure 1b shows a perspective view. Figure 1c shows a second broken-away view. [Figure 7] This is an exemplary embodiment of a heating element incorporated in the system of the present invention. Figure 2a shows an example of a heating pad including a wound heating element. Figure 2b shows an example of a heating pad including an etched foil heating element. [Figure 8] This is a graph showing the simulated effect of the power of the heating means included in an exemplary embodiment of the device (SolidWorks) of the present invention. Figure 3a shows the thermal distribution of the device. Figure 3b shows the temperature of the device as a function of the power-on time of the heating means. [Figure 9] This is a graph showing the simulated effect of the power of the heating means included in an exemplary embodiment of the system (SolidWorks) of the present invention. Figure 4a shows the thermal distribution of the system. Figure 4b shows the temperature of the system as a function of the power-on time of the heating means. MODE FOR CARRYING OUT THE INVENTION

[0248] References [1]MOSDZIANOWSKI,C.,et al.Epimerization study on[18F]FDG produced by an alkaline hydrolysis on solid support under stringent conditions.Applied radiation and isotopes,2002,56.6:871-875. [2] U.S. Patent No. 8476063B2 [3] U.S. Patent Application Publication No. 20020183660A1 [4] U.S. Patent No. 9408257B2 [5] KR101320762B1 specification [Examples]

[0249] The following examples are provided for illustrative purposes only and do not limit the scope of the present invention in any way.

[0250] Example 1: Manual reaction Manual process description The series of experiments described herein aimed to reproduce preliminary results obtained from a “cold” synthesis of the SGMIB linker using a heated cartridge during the deprotection step (= cold experiments conducted by ORA). Following this first proof of concept, a series of manual “hot” syntheses using a heated cartridge were performed (= radioactive experiments conducted by Camel-IDS), which will be described in detail below.

[0251] In the examples detailed below, Boc2-N-succinimidyl-4-guanidinomethyl-3-[( * )I] Iodobenzoate ([ * I]SGMIB-Boc2) describes the implementation of a novel method for deprotecting radioactive halogenating agents used to radioactively label target compounds. *I]SGMIB is obtained by the synthesis procedure shown in Figure 1. A detailed explanation of the deprotection procedure for the tC18 Sep-Pak cartridge is shown in Figure 2.

[0252] Using the presented series of experiments, the deprotection capability via the method according to the present invention, using a heated cartridge, will be evaluated as a function of reaction time and the type (and concentration) of acid used, with respect to varying reaction temperatures.

[0253] In process measurements, the deprotection performance and the quality of radioactive compounds are evaluated by gradient RP-HPLC analysis. The same chromatographic conditions are used even when evaluating fully automated procedures.

[0254] Raw materials and methods All reagents (N-chlorosuccinimide (NCS), tin precursor (SGMTB-Boc2), sodium iodide (Na) 127 I) 85% phosphoric acid (H3PO4), acetic acid (HOAc), and solvents (acetonitrile (ACN), ethanol (EtOH)) were commercially obtained from Merk-Sigma and used without further purification. Sep-Pak C18 Plus Short / Light cartridges for deprotection were commercially obtained from Waters.

[0255] Na[ 131 I]I was commercially obtained from GE Healthcare in the form of a 0.05 M NaOH solution with a volume radioactivity intensity of 800 μCi / μL (29.6 MBq / μL). UV / Radio-HPLC analysis was performed on a Shimadzu LC-20AT liquid chromatography system equipped with a C-18 column (X-Select, CSH, C18, 3.5 μ, 100 × 4.6 mm) at a flow rate setting of 1.50 mL / min, using the following gradient: t=0: 90% A, 10% B; t=15 min: 100% B (where A = H2O + 0.05% TFA, B = ACN + 0.05% TFA).

[0256] General experimental protocols a) Preparation of Na 131 For a 10 mL vial: 1. Add 1.20 μL of H2O (WFI). 2. Add the desired amount of cold iodine (Na 127 I). 3. Add 3.5 μL of 10-fold diluted PBS solution. 4. Add the radioactive iodine (Na 131 I) with the desired radioactivity intensity. → Evaporate at 45 °C until dry. b) Labeling step For the dried Na 131 I in a 10 mL vial: 1. Add the desired amount of oxidizing agent solution (NCS). 2. Add the desired amount of tin precursor solution (SGMTB - Boc2). → Labeling time: 5 min / 23 °C 3. QC HPLC: 10 μL of the labeling solution (V inj : 100 μL) in 90 μL of H2O + 0.05% TFA. c) Concentration and deprotection step (SGMIB - Boc2) For the labeling solution in a 10 mL vial: 1. Dilute with the desired volume of H2O (WFI). 2. Load the diluted labeling solution onto the desired tC18 cartridge. 3. Rinse the tC18 cartridge with the desired volume of H2O (WFI). 4. Dry the tC18 cartridge using air. 5. Add the desired volume of 85% phosphoric acid (H3PO4) to the tC18 cartridge. 6. After sealing with two stoppers, add the tC18 cartridge to a water bath. → Deprotection time: 20 min / desired temperature. d) Elution step of the final product (SGMIB) For the tC18 cartridge (Sep - Pak): 7. Wash with the desired volume of H2O (WFI). 8. Dry using the atmosphere. 9. Using the desired volume of EtOH / H2O(70 / 30)+1%HOAc, the final product ( 131 Elute I-SGMIB. 10. QC HPLC: 10 μL of eluent (V) in 90 μL of H2O + 0.05% TFA inj (100 μL).

[0257] Experimental conditions (manual) + results table As described above, the deprotection performance using a heated cartridge is evaluated using the presented series of experiments, varying the reaction temperature from 23°C to a maximum of 75°C. The corresponding results (deprotection yield) can be found in the table below. The relevant RP-HPLC chromatograms are described in Part 3.

[0258] The first result shows that within the temperature range of 23°C to 75°C, the measured deprotection yield is greater than 75% with a deprotection time of 20 minutes. Within the range of 32°C to 75°C, the deprotection yield increases to greater than 92%, while within the range of 40°C to 75°C, the measured yield exceeds 99%.

[0259] With a deprotection time of 5 minutes and a temperature range of 23°C to 55°C, the expected deprotection yield is over 30%. In the range of 40°C to 75°C, the yield increases to over 73%, while in the range of 55°C to 75°C, measured yields exceed 99%.

[0260] The important point here is that radioactive iodine is produced in a reaction mixture consisting of either EtOH / HOAc or ACN / HOAc. * Regarding I]SGMIB, efficient heated cartridge deprotection was demonstrated. These experiments suggested that the observed deprotection efficiency was independent of the composition of the radioactive iodation reaction mixture (which is performed before deprotection).

[0261] Table 1 outlines the experimental procedures, while Table 2 lists the results obtained for each of these experiments.

[0262] In addition, the RP-HPLC results showed that when the deprotection reaction was carried out at 75°C, the impurities were [ * This indicates that the proportion of [I]SGMIB is observed to be in the range of 3–12%. This impurity does not form in the deprotection reaction at 40°C (less than 1%).

[0263] [Table 1]

[0264] [Table 2]

[0265] [Table 3]

[0266] [Table 4]

[0267] [Table 5]

[0268] [Table 6]

[0269] The progression of the deprotection yield after heating (20 minutes) can be seen in Figure 3. The progression of the deprotection yield after heating (20 minutes) can be seen in Figure 4.

[0270] Several reaction parameters are observed to affect the deprotection yield.

[0271] Parameter 1. Temperature: • Deprotection time: 20 minutes Within the temperature range of 23°C to 75°C, the measured deprotection reaction yield was greater than 75%. Within the temperature range of 32°C to 75°C, the measured deprotection reaction yield was greater than 92%. Within the temperature range of 40°C to 75°C, the measured deprotection reaction yield was greater than 99%. • Deprotection time: 5 minutes Within the temperature range of 23°C to 55°C, the measured deprotection reaction yield was greater than 30%. Within the temperature range of 40°C to 75°C, the measured deprotection reaction yield was greater than 73%. Within the temperature range of 55°C to 75°C, the measured deprotection reaction yield was greater than 99%.

[0272] Side reaction product pair ( 131 I) SGMIB: Deprotection reaction at 75°C for 20 minutes: Side reaction product pair ( 131 I) SGMIB range: 3-12% Deprotection reaction at 30-40°C for 20 minutes: Side reaction product pair ( 131 I) SGMIB less than 1%.

[0273] Example 2: Automated reaction The experimental examples described were obtained using an ORA Neptis synthesizer and a fully automated procedure with an integrated cartridge heater. These experiments were intended to replicate results obtained through manual synthesis.

[0274] The effectiveness of deprotection at different temperatures and reaction times was evaluated by performing HPLC analysis of the obtained reaction products using the same chromatographic conditions as in manual synthesis.

[0275] In the examples detailed below, Boc2-N-succinimidyl-4-guanidinomethyl-3-[( * )I] Iodobenzoate ([ *I)I-SGMIB-Boc2) describes the implementation of a novel method for deprotecting radioactive halogenating agents used to radioactively label target compounds.

[0276] Raw materials and methods The manual synthesis was translated into a sequence that could be used on the ORA Neptis synthesizer. This specialized synthesizer for radiopharmaceuticals allows for the reproduction of manual synthesis in automated mode, using disposable equipment called "cassettes" prepared before each experiment, and a predetermined sequence of several "steps." By designing appropriate cassettes and sequences of steps, reproducible radiochemical synthesis becomes possible. The layout of the cassettes used in the experimental examples detailed below can be found in Figure 5.

[0277] The cassette consists of a manifold ensemble including a single-use three-way valve, on which various consumables are provided, such as non-consumable vials filled with reagents, solid-phase extraction (SPE) or anion exchange cartridges, or syringes. Each step consists of a series of setting points (including, for example, the valve position, the syringe position, the applied nitrogen pressure and flow rate, the oven temperature, or the start of the vacuum pump), which are applied over a predetermined period of time.

[0278] The following paragraphs describe the complete "template" sequence. Specific parameters that vary among experimental examples are described in more detail in Table 3. The results of various experimental examples are shown in Table 5.

[0279] Fully automated sequences describing different steps: A. Before radiosynthesis, a solution containing radioactive isotopes is placed in the reactor (position 13). B. The solution is dried by heating the reactor using a nitrogen stream. C. Next, the precursor and oxidizing agent are transferred into the reactor (position 15). D. In that reactor, a radioactive labeling reaction is carried out. E. The reaction mixture is diluted with water (position 12) using a 10 mL syringe (position 7), and the diluted solution thus obtained is then loaded onto a tC18 cartridge (position 8). The eluent obtained from the tC18 cartridge is sent to the waste disposal. F. Rinse the reactor and tC18 cartridge with water (position 12) using a 10 mL syringe (position 7). Using a 10 mL syringe (position 7), load the acid onto the tC18 cartridge (position 6). Once the tC18 cartridge is saturated with acid, close the valve at position 9 to keep the acid on the tC18 cartridge during deprotection. H. The cartridge is heated for a predetermined time to enable deprotection on the tC18 cartridge. I. Rinse the tC18 cartridge with water (position 12) using a 10 mL syringe (position 7) to force any remaining acid and eluent into the waste. Using a 10 mL syringe (position 7), load the eluent for collection onto the tC18 cartridge (position 10). Collect the eluent in the sample collection vial (position 5).

[0280] [Table 7]

[0281] [Table 8]

[0282] The fully automated sequence described above then produces a pure [ ] consisting of EtOH / water (70 / 30) plus 1% AcOH. *[I]I-SGMIB can be eluted into a conjugation vial containing an appropriate amount of the target compound in a conjugation buffer. After conjugation, [ * The I]I-SGMIB-labeled target compound is purified using a cartridge and eluted into a formulation buffer ready for end-use. This part of the process has recently been incorporated into the synthesis sequence. Boc2-protected [ * An example of a cassette used to automate the thermal deprotection of I]I-SGMIB can be seen in Figure 5.

[0283] chromatography conditions UV / Radio-HPLC analysis was performed on a Shimadzu LC-20AT liquid chromatography system equipped with a C-18 column (X-Select, CSH, C18, 3.5 μm, 100 × 4.6 mm) at a flow rate of 1.50 mL / min, using the following gradient: t=0: 90% A, 10% B; t=15 min: 100% B (where A = H2O + 0.05% TFA, B = ACN + 0.05% TFA).

[0284] Detailed information on HPLC features: • HPLC: Shimadzu LC-20AT-Prominence Liquid Chromatography →Gradient and solvent • UV detector: Shimadzu SPD-20A-Prominence UV / VIS detector →Dual detection: 220nm / 254nm • Radiation detector: Elysia RAYTEST Sockel 3”GABI Nova 1.0 →RA detection: 5μL loop • HPLC column: X-Select, CSH, C18, 3.5μ, 100×4.6mm • Rheodyne Injector: 100 μL PEEK-Loop Software: GINA XStation, Gabi Nova 31038.

[0285] Each sample was injected into the same solvent mixture under initial HPLC operating conditions. H2O / ACN + 0.05% TFA (90 / 10) Reactants / Cold data (references): Reaction products: UV chromatogram (220-254 nm).

[0286] [Table 9]

[0287] result The experimental results are shown in Table 5.

[0288] [Table 10]

[0289] These initial results indicate that a deprotection yield of over 99% was obtained after reactions at both 75°C and 60°C, and after only 20 minutes of incubation.

[0290] Using this novel invention, radioactive iodine is produced in a reaction mixture consisting of either EtOH / HOAc or ACN / HOAc. * For I]SGMIB, efficient heated cartridge deprotection was demonstrated. These experiments suggested that the observed deprotection efficiency was independent of the composition of the radioactive iodine reaction mixture (which is carried out before deprotection). In addition, RP-HPLC results showed that when the deprotection reaction was carried out at 75°C, the impurity [ * This indicates that the proportion of [I]SGMIB is observed to be in the range of 3–12%. This impurity does not form in the deprotection reaction at 40°C (less than 1%).

[0291] These findings are not exemplary and are in contrast to the conventional method for deprotection (in this case, after radioiodination in EtOH / HOAc, the deprotected * I]I-SGMIB which corresponds to only about 30%). In addition, in the latter case, the impurity level is much higher, in the range of about 25% as opposed to less than 1% in the case of the method according to the invention.

[0292] Example 3: Exemplary Device According to the Invention FIG. 6 shows various views of an exemplary embodiment of device 1 and system 10 in the present invention. FIG. 6a is a first broken-away view. FIG. 6b is a perspective view. FIG. 6c is a second broken-away view.

[0293] Device 1 houses a chemical reaction vessel 3 containing a mixture (not shown) and is capable of being heated. As shown in FIG. 6, system 10 includes device 1 and chemical reaction vessel 3, which are sized in diameter and length such that device 1 surrounds chemical reaction vessel 3 and heat generated inside heating means 5 contained within device 1 can be transferred to chemical reaction vessel 3. For this purpose, device 1 includes an opening 2 configured to receive the reaction vessel 3 and heating means 5 that at least partially surrounds the opening. In the embodiment shown in this figure, the chemical reaction vessel 3 is a cartridge. In an embodiment, the cartridge is a SPE cartridge. Chemical reaction vessel 3 includes a reactor chamber 30, an inlet 31, a housing 33, and an outlet 32.

[0294] Heating means 5 (which may be, for example, an embodiment of the heating means according to Example 2 and FIG. 7) includes a polymer 9 for thermal insulation and a resistance conductor 8 embedded in the polymer 9 for thermal insulation.

[0295] Device 1 is configured to heat the mixture present in the chemical reaction vessel 3, which contains the mixture, according to predetermined temperature requirements by applying an electric current to the heating means 5 when the chemical reaction vessel 3 containing the mixture is present in the opening 2.

[0296] Device 1 includes a metal sleeve 4 placed between the chemical reaction vessel 3 and the heating means 5, surrounding the chemical reaction vessel. In embodiments, the metal is copper.

[0297] The use of copper metal sleeves is shown in Figures 8 and 9, which demonstrate the simulated effect of the power-heating means.

[0298] The heating means 5 includes an adhesive layer for attaching the heating means 5 to the metal sleeve 4. This has advantages such as easier installation of the device, and / or improved structural integrity of the device, and / or improved thermal conductivity for heat transfer from the heating means to the metal sleeve. The device 1 also includes a cover 6. The cover 6 is convenient for assembling the device. In this embodiment, one or more holes 60 are included for supplying power to the heating pad 3.

[0299] In an embodiment, the device 1 includes a control unit and a temperature sensor, wherein the control unit is configured to maintain a predetermined temperature requirement in relation to the temperature of the mixture, such that it falls within a predetermined sub-range, preferably 30°C to 80°C, and more preferably 30°C to 50°C, by controlling the power supplied to the heating means 5 based on measurements by the temperature sensor. In a preferred embodiment, the predetermined temperature requirement relates to reaching a stable temperature after a rapid and short equilibrium time, preferably without any overheating.

[0300] In the embodiment shown in Figure 6, device 1 is a cylindrical sleeve, and opening 2 is a lumen surrounded and defined by the device. In the embodiment, the heating means has a maximum dimension from 10 mm to a maximum of 200 mm, preferably from 20 mm to a maximum of 100 mm. Thereafter, the length and / or resistance and / or maximum output of the resistive conductor is adapted as a function of the dimensions and / or requirements of the chemical reaction vessel selected for use with the device and / or predetermined temperature requirements.

[0301] The chemical reaction vessel 3 further includes a solid phase (not shown) suitable for acting as a facilitator in the chemical reaction. In embodiments, the chemical reaction vessel 3 includes a metal and / or a metal alloy and / or glass and / or glass fiber and / or an organic polymer. In a preferred embodiment in this example, the chemical reaction vessel 3 consists of one or more organic polymers. In embodiments, the solid phase is silica, preferably one or more of Sep-Pak tC18, Step-Pak C18, Oasis HLB, Oasis MCX, Oasis MAX, and Sephadex LH-20. In a preferred embodiment in this example, the solid phase is Sep-Pak tC18.

[0302] In this embodiment, the mixture is introduced through the inlet 31, and power is supplied to the heating means 5 to cause a chemical reaction facilitated by the solid phase inside the reaction chamber 30, after which the mixture is withdrawn through the outlet 32. In this embodiment, the mixture contains a radioactive compound, and the chemical reaction is a chemical reaction of the radioactive compound facilitated by the solid phase.

[0303] The predetermined temperature requirements might, for example, require that the chemical reaction vessel reach a target temperature of 50°C within 3 minutes, starting from an initial temperature of 30°C, 40°C, 50°C, 60°C, or 70°C. These predetermined temperature requirements might further specify that the maximum time required to transition from 60°C to 50°C is 3 minutes, with any over-temperature exceeding 1°C.

[0304] In this example, the temperature requirement is met by means of a control unit, which is a programmable logical controller (PLC) with a 24V power supply. In this example, because the power of the heating means is low, heat is supplied directly by the controller. The temperature is measured by means of temperature sensors, including a thermocouple board in the PLC. The control unit is configured to control the temperature according to PID control. This relates to specific parameters configured to avoid overheating.

[0305] Example 4: Example of heating means in the present invention Figure 7 shows exemplary embodiments of the heating pad 5 as a heating element in the present invention. Figure 7a shows a first embodiment of the heating pad including a wound heating element. Figure 7b shows a second embodiment of the heating pad including an etched foil heating element. Any of these embodiments can be combined, for example, with the heating means of Example 1, or with one of the heating means of device 1 of Example 1.

[0306] All embodiments relate to a heating pad 5 comprising a thermal insulation polymer 9 and a resistive conductor 8. In this case, the first embodiment provides a resistive conductor 8 including a wound heating element, while the second embodiment provides a resistive conductor 8 including an etched foil resistive conductor. In a third embodiment of the present invention (not shown), the resistive conductor 8 includes both one or more wound heating elements and one or more etched foil resistive conductors. In the embodiment, the resistive conductor has an insulation resistance greater than 100 kΩ, preferably greater than 1 MΩ, and preferably at least 10 MΩ. In the embodiment, its power rating is from 0.1 W to a maximum of 10 W, preferably from 0.5 W to a maximum of 4 W, more preferably about 1 W, 1.25 W, 1.50 W, 1.75 W, or 2 W.

[0307] In the embodiment, the thermal insulation polymer 9 includes silicone and / or polyimide. The thermal insulation polymer 9 in the second embodiment of Figure 7b may be different from, or the same as, that in the first embodiment of Figure 7a. In the embodiment, the thermal insulation polymer 9 includes both silicone and polyimide. It is preferable that the thermal insulation polymer 9 consists of silicone or polyimide. In the embodiment, the melting temperature of the thermal insulation polymer is higher than 150°C, preferably higher than 200°C.

[0308] In exemplary embodiments, the heating pad 5 is a flexible sheet having a rectangular shape. The thickness of the flexible sheet is 0.5 mm to a maximum of 1.5 mm, and in some examples, 0.5 mm to a maximum of 1.0 mm. In exemplary embodiments, the thickness is 0.7 mm. The flexible sheet includes a reinforcing layer covering one side of the flexible sheet. Preferably, the reinforcing layer is made of glass and / or glass fiber.

[0309] In exemplary embodiments, the heating pad includes an adhesive layer for attaching the heating pad to a further position on the device. In the device of Example 1, this may be a metal sleeve 4 or cover 6 surrounding the heating means.

[0310] Figure 7a shows an embodiment of the heating pad 5, which includes an insulating polymer 9 and a wound heating element 8. Such an element 8 can be made, for example, by winding a resistance wire around a fiberglass cord and then arranging the element 8 on the insulating polymer 9 in a predetermined pattern. However, as is known to those skilled in the art, other methods for making such an element are also possible. In an exemplary embodiment, the pattern relates to one or more spirals unfolded on each part of the insulating polymer 9.

[0311] Figure 7b shows an embodiment of a heating pad 5 comprising a thermal insulation polymer 98 and an etched foil element 6. In such embodiments, the element is preferably created by etching a pattern onto a corrosion-resistant nickel alloy foil, where the pattern is a circuit. However, as is well known to those skilled in the art, other methods for creating such elements are also possible. In exemplary embodiments, the pattern involves a curve or spiral, including numerous bends, for example, 10 or more bends.

[0312] In embodiments, the pattern is as follows: the maximum total length of the resistive conductor is at least twice, preferably at least five times, and more preferably about ten times, the maximum dimensions of the heating means. In exemplary embodiments, the heating means has a maximum dimension of 50 mm, for example, 10 mm × 50 mm, 25 mm × 50 mm, or 40 mm × 50 mm. In other exemplary embodiments, the heating means has a maximum dimension of 30 mm, for example, 5 mm × 30 mm, 15 mm × 30 mm, or 20 mm × 30 mm. In embodiments, the heating means has a maximum dimension from 10 mm to a maximum of 200 mm, preferably from 20 mm to a maximum of 100 mm. In embodiments, the maximum total length of the resistive conductor is at least twice the maximum dimensions of the heating means, for example, 50 mm, 100 mm, 200 mm, 300 mm, 500 mm, or 800 mm. In the embodiment, the minimum dimension, i.e., the thickness of the heating means, is from 0.1 mm to a maximum of 3.0 mm, preferably from 0.5 mm to a maximum of 1 mm, preferably about 0.6 mm, 0.7 mm, 0.8 mm, or 0.9 mm.

[0313] In exemplary embodiments, including the first and second embodiments of this example, the convex hull structure of the pattern covers at least 50%, more preferably at least 80%, of the surface of the insulating polymer 9. In embodiments, one or more of each helices or bends, preferably one, two, two or more, four or five or more, are unfolded over each portion of the insulating polymer 9, with at least 50%, preferably at least 80%, of their respective surfaces covered.

[0314] Power is supplied to the heating pad 5 via wires attached to it through holes in the cover 6, causing the heating pad to heat up. When the heating pad is used in a device and / or system such as in Example 1, heat is transferred to the chemical reaction vessel via conduction. The heating of the chemical reaction vessel by supplying power to the heating pad 5 is controlled by means of a control unit and a temperature sensor.

Claims

1. 1. A method for obtaining a radiolabeled polymer of amino acids using a radioactive compound, said compound comprising a protecting group, said compound being included in a mixture, said method comprising: (a) contacting said mixture with a solid phase, whereby said radioactive compound is attached to said solid phase, followed by (b) heating the mixture to a temperature selected in the range of 30° C. up to 150° C., whereby the protecting groups are hydrolytically removed from the radioactive compound, the deprotected radioactive compound remaining attached to the solid phase at the end of this step; (c) attaching a polymer of amino acids to the deprotected radiolabeled compound obtained at the end of step (b), resulting in a polymer of radiolabeled amino acids by said attachment: During steps (a) and (b), any solution that contacts the solid phase is a neutral or acidic solution; said radioactive compound does not contain fluorine-18; method.

2. 2. The method of claim 1, wherein the eluent in step (c) is selected from the group consisting of an aqueous solution, an organic solvent, or a mixture thereof.

3. The method of claim 2, wherein the organic solvent is a mixture of water and ethanol.

4. The method according to claim 2 or 3, wherein the organic solvent is ethanol.

5. 3. The method of claim 1 or 2, wherein the method comprises hydrolysis of the radioactive compound, the hydrolysis occurring during the heating, and the hydrolysis being acid hydrolysis.

6. The method of claim 5, wherein the acid hydrolysis comprises the use of an acid selected from the group consisting of phosphoric acid, hydrochloric acid, sulfuric acid, trifluoroacetic acid, and aqueous mixtures thereof.

7. The method of claim 6, wherein the acid hydrolysis comprises the use of an acid selected from the group consisting of phosphoric acid, hydrochloric acid, sulfuric acid, and aqueous mixtures thereof.

8. The method of claim 7, wherein the acid is 80% by weight phosphoric acid.

9. The method of claim 1, wherein the protecting group is selected from the group consisting of tert-butyl carbamate (t-Boc or Boc), tert-butyl ester (OtBu), benzyl ester (BzO), benzylidene, tetrahydropyranyl ether (THP), acetal, trityl (Trt), and methoxymethyl ether (MOM).

10. The method of claim 9, wherein the protecting group is tert-butyl carbamate (t-Boc or Boc).

11. 2. The method of claim 1, wherein the temperature is selected in the range of 30° C. up to 70° C.

12. The method of claim 11, wherein the temperature is selected in the range of 30°C to a maximum of 55°C.

13. The method of claim 12, wherein the temperature is selected in the range of 30°C up to 70°C and the heating time is selected in the range of 1 minute up to 15 minutes.

14. The method of claim 13, wherein the temperature is selected in the range of 30°C up to a maximum of 55°C and the heating time is selected in the range of 1 minute up to a maximum of 10 minutes.

15. The method of claim 1, wherein the polymer of amino acids is a peptide, a protein scaffold, or an antibody or fragment thereof.

16. The method of claim 15 , wherein the polymer of amino acids is an antibody or a fragment thereof.

17. The method of claim 16, wherein the polymer of amino acids is a diagnostic and / or therapeutic compound.

18. The method of claim 17, wherein the diagnostic and / or therapeutic compound targets an antigen expressed in a cell.

19. The method of claim 18, wherein the cell is a tumor cell.

20. The method described in claim 18 or 19, wherein the antigen is HER2.

21. The method of claim 16, wherein the antibody or fragment thereof is a heavy chain variable domain derived from a heavy chain antibody (VHH), or a fragment thereof.

22. The method of claim 21, wherein the heavy chain antibody (VHH) or fragment thereof has at least 80% amino acid identity or has amino acid sequence number 7 or sequence number 8.

23. 2. The method of claim 1, wherein the radioactive compound is selected from the group consisting of α-emitters and β-emitters.

24. The method of claim 23, wherein the radioactive compound comprises a radioactive nuclide selected from the list consisting of hydrogen-3, astatine-211, carbon-11, carbon-14, bromine-76, iodine-123, iodine-124, iodine-125, iodine-131, phosphorus-32, and sulfur-35.

25. The method of claim 24, wherein the radioactive nuclide is selected from the group consisting of astatine-211, iodine-123, iodine-124, and iodine-131.

26. 2. The method of claim 1, wherein the radioactive compound is N-succinimidyl-4-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3-[(131)I]iodobenzoate (Boc2-[131I]SGMIB).

27. The method of claim 26, wherein N-succinimidyl-4-(1,2-bis(tert-butoxycarbonyl)guanidino)methyl-3-[(131)I]iodobenzoate (Boc2-[131I]SGMIB) is converted to N-succinimidyl-4-guanidinomethyl-3-[(131)I]iodobenzoate ([131I]SGMIB) during heating in at least 30% yield as determined by quantitative HPLC, and the heating time is selected from the range of 1 minute to 10 minutes.

28. The method of claim 27, wherein the heating time is selected from the range of 1 minute up to 5 minutes.

29. A device (1) for accommodating and heating a reaction vessel (3) containing a mixture, said device (1) comprising a heating means (5) and an opening (2) configured to accommodate said chemical reaction vessel (3), said heating means (5) at least partially surrounding said opening; The heating means (5) comprises: - polymers for thermal insulation (9), - a resistive conductor (8) embedded in said insulating polymer; Including; said device (1) being configured, when said reaction vessel (3) containing said mixture is present in said opening (2), to heat said mixture present in said reaction vessel according to a predetermined temperature requirement by energizing said heating means (5), Preferably, the device (1) is a cylindrical sleeve and the opening is a lumen surrounded by the device (1). Device (1).

30. The insulating polymer (9) is silicone or polyimide, preferably the melting temperature of the insulating polymer (9) is higher than 150° C., preferably higher than 200° C. Preferably, the resistive conductor (8) is an etched foil heating element or a wire-wound heating element; and / or Preferably, the heating means (5) is a flexible sheet, more preferably, said flexible sheet has a rectangular shape; more preferably, the thickness of said flexible sheet is from 0.5 mm up to 1.5 mm, most preferably from 0.5 mm up to 1.0 mm, and / or More preferably, the flexible sheet comprises a reinforcing layer covering one side of the flexible sheet, and most preferably, the reinforcing layer consists of glass and / or glass fibres; 30. The device (1) according to claim 29.

31. 31. The device (1) according to claim 29 or 30, wherein the device comprises a metal sleeve (4) placed between the heating means and the opening and surrounding the opening.

32. The device (1) described in claim 31, wherein the metal is copper.

33. 31. The device (1) according to claim 29 or 30, wherein said device (1) comprises a control unit, preferably further comprising a temperature sensor, said control unit being configured to maintain said predetermined temperature requirement in relation to the temperature of said mixture to be in a predetermined sub-range comprised in the range 30°C to 150°C, preferably 30°C to 80°C, more preferably 30°C to 50°C, by controlling the power supplied to said heating means based on measurements by said temperature sensor, preferably said control being based on measurements by said temperature sensor.

34. A system (10) for obtaining radiolabeled polymers of amino acids by carrying out a reaction in a mixture, comprising: - a device (1) according to claim 29 or 33; a reaction vessel (3) placed in the opening (2) of the device (1), said reaction vessel (3) comprising a chamber (30), an inlet (31) and preferably a solid phase suitable to act as a facilitator during said reaction, said system (10) being configured to heat the mixture present in said reaction vessel (3) according to a predetermined temperature requirement by energizing said heating means (5) when said mixture is inserted into said chamber (30) through said inlet (31), thereby causing said reaction to occur in said chamber (30); Preferably, the chemical reaction vessel (3) further comprises an outlet (32). System (10).

35. The system (10) of claim 34, wherein the chemical reaction vessel is an SPE cartridge.

36. A method according to claim 1, comprising the use of a device as described in claim 29 or a system as described in claim 34, wherein the heating of the mixture in step (b) is achieved by applying an electrical charge to a heating means included in the device or system.

37. 37. The method of claim 1 or 36, or the device of claim 29, or the system of claim 34, wherein the solid phase used in step (a) of the method or included in the device or method is silica.

38. The method of claim 37, wherein the silica is selected from the group consisting of Sep-Pak tC18, Step-Pak C18, Oasis HLB, Oasis MCX, Oasis MAX, Sephadex LH-20, and combinations thereof.

39. The method of claim 38, wherein the silica is Sep-Pak tC18.